Novartis  Research  and Development  
BAF312A/Siponimod/Mayzent® 
Clinical Trial Protocol CBAF312AUS02 / [STUDY_ID_REMOVED]
Exploring the safety and tolerabilit y of conversion from 
oral, injecta ble or infusion disease modifying therapies to 
dose-titrated Oral Siponimod (Mayzent®) in patients with 
advancing forms of relapsing multiple sclerosis: A 6-month 
open label, multi-center Phase IIIb stud y (EXCHANGE) 
Document  type:  Amendment  Protocol  Version  
EUDRACT  number:  N/A 
Version  number:  v05 clean  
Clinical  Trial Phase:  IIIb 
Release  date:  27-Jul-2021  
Property  of Novartis 
Confidential  
May not be used,  divulged,  published,  or otherwise  disclosed 
without the consent of Novartis  
Clinical  Trial  Protocol  Template  Version  1.0 (01-Dec-2017)  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  2  
Protocol  No. CBAF312AUS02   
 
Table  of contents  
Table  of contents  ................................ ................................ ................................ ..................  2 
List of tables ................................ ................................ ................................ .........................  6 
List of figures  ................................ ................................ ................................ .......................  7 
List of abbreviations  ................................ ................................ ................................ ............  8 
Glossary  of terms  ................................ ................................ ................................ ...............  11 
Amendment  05 ................................ ................................ ................................ ...................  13 
Amendment  04 ................................ ................................ ................................ ...................  14 
Amendment  03 ................................ ................................ ................................ ...................  16 
Amendment  02 ................................ ................................ ................................ ...................  20 
Amendment  01 ................................ ................................ ................................ ...................  22 
Protocol summary  ................................ ................................ ................................ ..............  24 
1 Introduction  ................................ ................................ ................................ ........................  32 
1.1 Background  ................................ ................................ ................................ ..........  32 
1.2 Purpose  ................................ ................................ ................................ .................  35 
2 Objectives  and endpoints  ................................ ................................ ................................ ... 35 
3 Study  design  ................................ ................................ ................................ .......................  37 
  38 
4 Rationale  ................................ ................................ ................................ ............................  39 
4.1 Rationale  for study  design ................................ ................................ ....................  39 
  40 
4.2 Rationale for dose/regimen and duration of treatment  ................................ ........  41 
4.3 Rationale for choice of control drugs  ................................ ................................ .. 42 
4.4 Purpose  and timing  of interim  analyses/des ign adaptations  ................................  42 
4.5 Risks  and benefits  ................................ ................................ ................................  42 
4.6 Rationale for public health emergency  mitigation procedures  ............................  43 
5 Population  ................................ ................................ ................................ ..........................  43 
5.1 Inclusion  criteria  ................................ ................................ ................................ .. 43 
5.2 Exclusion criteria  ................................ ................................ ................................ . 44 
6 Treatment  ................................ ................................ ................................ ...........................  48 
6.1 Study  treatment  ................................ ................................ ................................ .... 48 
6.1.1 Investigational  and control  drugs  ................................ ..........................  48 
6.1.2 Additional study  treatments  ................................ ................................ ... 49 
6.1.3 Treatment  arms/group  ................................ ................................ ............  49 
6.1.4 Treatment duration  ................................ ................................ ................  49 
6.2 Other  treatment(s)  ................................ ................................ ................................  49 
6.2.1 Concomitant  therapy ................................ ................................ ..............  49 

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  3  
Protocol  No. CBAF312AUS02   
6.2.2 Prohibited  medication  ................................ ................................ ............  50 
6.3 Treating  the patient  ................................ ................................ ..............................  50 
6.3.1 Patient  numbering  ................................ ................................ ..................  50 
6.3.2 Treatment  assignment  ................................ ................................ ............  51 
6.4 Treatment blinding  ................................ ................................ ...............................  51 
6.5 Dose  escalation  and dose modification  ................................ ................................  51 
6.6 Additional  treatment  guidance  ................................ ................................ .............  51 
6.6.1 Treatment compliance  ................................ ................................ ...........  51 
6.6.2 Emergency  breaking of assigned treatment code ................................ .. 51 
6.7 Preparation  and dispensation  ................................ ................................ ................  51 
6.7.1 Handling of study  treatment and additional treatment  ..........................  52 
6.7.2 Instruction  for prescribing  and taking  study  treatment  ..........................  52 
7 Informed  consent  procedures  ................................ ................................ .............................  53 
8 Visit  schedule  and assessments  ................................ ................................ ..........................  54 
8.1 Screening ................................ ................................ ................................ ..............  62 
8.1.1 Information  to be collected  on screening  failures  ................................ .. 62 
8.2 Patient  demographics/other  baseline  characteristics  ................................ ............  63 
8.3 Efficacy/Pharmacodynamics  ................................ ................................ ................  63 
  63 
8.4 Safety/Tolerability  ................................ ................................ ................................  63 
8.4.1 Laboratory  evaluations  ................................ ................................ ..........  64 
8.4.2 Electrocardiogram (ECG) ................................ ................................ ...... 66 
8.4.3 Optical  Coherence  Tomography  (OCT)  ................................ ................  66 
8.4.4 Pregnancy  and assessments of  infertility  ................................ ...............  67 
8.4.5 Other safety  evaluations  ................................ ................................ ........  67 
8.5 Additional  assessments  ................................ ................................ ........................  69 
8.5.1 Clinical  Outcome  Assessments  (COAs)  ................................ ................  69 
  69 
8.5.3 Other  Assessments  ................................ ................................ .................  70 
9 Study  discontinuation and completion  ................................ ................................ ...............  70 
9.1 Discontinuation  ................................ ................................ ................................ .... 70 
9.1.1 Discontinuation of study  treatment  ................................ .......................  70 
9.1.2 Withdrawal  of informed consent  ................................ ...........................  71 
9.1.3 Lost to follow -up ................................ ................................ ...................  71 
9.1.4 Early  study  termination  by sponsor  ................................ .......................  71 
9.2 Study  completion and post study  treatment  ................................ .........................  71 
10 Safety  monitoring and reporting  ................................ ................................ ........................  72 

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  4  
Protocol  No. CBAF312AUS02   
10.1 Definition  of adverse  events  and reporting  requirements  ................................ .... 72 
10.1.1  Adverse  events ................................ ................................ .......................  72 
10.1.2  Serious  adverse  events  ................................ ................................ ...........  73 
10.1.3  SAE reporting  ................................ ................................ ........................  74 
10.1.4  Pregnancy  reporting  ................................ ................................ ...............  74 
10.1.5  Reporting  of study  treatment  errors  including  misuse/abuse  .................  75 
10.2 Additional Safety  Monitoring  ................................ ................................ ..............  75 
10.2.1  Liver  safety  monitoring  ................................ ................................ .........  75 
10.2.2  Prospective suicidality  assessment  ................................ ........................  76 
10.2.3  Bradycardia  ................................ ................................ ............................  77 
11 Data  Collection  and Database  management  ................................ ................................ ....... 77 
11.1 Data  collection  ................................ ................................ ................................ ..... 77 
11.2 Database management and quality  control  ................................ ..........................  77 
11.3 Site monitoring ................................ ................................ ................................ ..... 78 
11.4 Virtual  patient  cohort  ................................ ................................ ...........................  78 
12 Data  analysis  and statistical  methods  ................................ ................................ .................  79 
12.1 Analysis  sets ................................ ................................ ................................ .........  79 
12.2 Patient  demographics  and other  baseline  characteristics  ................................ ..... 80 
12.3 Treatments  ................................ ................................ ................................ ............  80 
12.4 Analysis  of the primary  endpoint(s)  ................................ ................................ ..... 80 
12.4.1  Definition of primary  endpoint(s) ................................ ..........................  80 
12.4.2  Statistical  model,  hypothesis,  and method  of analysis  ..........................  80 
12.4.3  Handling  of missing  values/censoring/discontinuations  ........................  81 
12.4.4  Sensitivity  and Supportive  analyses  ................................ ......................  81 
12.5 Analysis  of secondary  endpoints ................................ ................................ ..........  81 
12.5.1  Safety  endpoints  ................................ ................................ ....................  81 
12.5.2  Patient  report  outcomes  ................................ ................................ .........  82 
  82 
12.7 Interim  analyses  ................................ ................................ ................................ ... 83 
12.8 Sample  size calculation  ................................ ................................ ........................  83 
12.8.1  Primary  endpoint(s)  ................................ ................................ ...............  83 
  84 
13 Ethical considerations and administrative procedures  ................................ .......................  84 
13.1 Regulatory  and ethical comp liance  ................................ ................................ ...... 84 
13.2 Responsibilities  of the investigator  and IRB/IEC  ................................ ................  84 
13.3 Publication of study  protocol and results  ................................ .............................  84 
13.4 Quality  Control and Quality  Assurance  ................................ ...............................  85 

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  5  
Protocol  No. CBAF312AUS02   
14 Protocol  adherence  ................................ ................................ ................................ .............  85 
14.1 Protocol  Amendments  ................................ ................................ ..........................  85 
15 References  ................................ ................................ ................................ ..........................  86 
16 Appendices  ................................ ................................ ................................ .........................  89 
16.1 Appendix  1: Vital  signs  ................................ ................................ .......................  89 
16.2 Appendix  2: Liver  event  definition  and follow  up requir ements  .........................  90 
16.3 Appendix  3: Specific  Renal  Alert  Criteria  and Actions  and Event  Follow -up .... 92 
16.4 Appendix 4: List of generic names of potent inhibitors/inducers of 
CYP2C9/CYP3A4  ................................ ................................ ...............................  94 
16.5 Appendix 5: Assessing Immunity  to Varicella  ................................ ....................  97 
16.6 Appendix 6:  Teriflunomide Accelerated Elimination Program (for patients 
treated  with teriflunomide  at scree ning or within  8 months  prior  to 
screening)  ................................ ................................ ................................ .............  97 
16.7 Appendix  7: Recommendations  for the management  of bradycardia  .................  98 
16.8 Appendix 8: Guide lines for Ophthalmic examination and management of 
Macular Edema  ................................ ................................ ................................ .... 99 

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  6  
Protocol  No. CBAF312AUS02   
 
 
List of tables  
Table 2-1 Objectives  and related  endpoints  ................................ ...........................  35 
Table  6-1 Core  Treatment  Period  ................................ ................................ ..........  49 
Table  6-2 Prohibited  medication  ................................ ................................ ............  50 
Table  6-3 Dose  and treatment  schedule  ................................ ................................ . 52 
Table  8-1 Assessment  Schedule  ................................ ................................ .............  57 
  61 
Table 8-3 Physical  Assessments  ................................ ................................ ............  64 
Table  8-4 Laboratory  Assessments  ................................ ................................ ........  64 
Table 10 -1 Guidance for capturing the study treatment errors including 
misuse/abuse  ................................ ................................ ..........................  75 
Table  16-1 Liver Event and Laboratory  Trigger Definitions  ................................ ... 90 
Table  16-2 Follow  Up Requirements  for Liver  Events  and Laboratory  Triggers  .... 90 
Table  16-3 Dual  moderate CYP2C9/strong  or moderate  CYP3A4 inhibitors  .........  94 
Table  16-4 Moderate  CYP2C9  inhibitors  ................................ ................................  94 
Table  16-5 Strong  CYP3A4  inhibitors ................................ ................................ ..... 94 
Table  16-6 Moderate  CYP3A4  inhibitor s ................................ ................................  95 
Table  16-7 Dual  moderate  CYP2C9/moderate  or strong  CYP3A4  inducers  ...........  95 
Table  16-8 Moderate  CYP2C9  inducers  ................................ ................................ .. 95 
Table  16-9 Strong  CYP3A4  inducers  ................................ ................................ ...... 96 
Table  16-10 Moderate  CYP3A4  inducers  ................................ ................................ .. 96 

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  7  
Protocol  No. CBAF312AUS02   
 
List of figures  
Figure  3-1 Siponimod Target Daily  Dose  ................................ ...............................  38 
Figure  3-2 Exchange  Study  Design  ................................ ................................ .........  38 

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  8  
Protocol  No. CBAF312AUS02   
List of abbreviations   
AE Adverse  Event  
AESI 
ALT Adverse  Events  of Special  Interest 
Alanine Aminotransferase  
ALP Alkaline  Phosphatase  
ANCOVA  Analysis  of covariance  
ARR Annualized  Relapse  Rate 
AST Aspartate  Aminotransferase  
AV Atrioventricular  
BAF312  Siponimod  
BBB Blood  Brain  Barrier  
BID Twice  a day 
BMI Body  Mass  Index  
BLRM  Bayesian  Logistic  Regression  Model  
BRACE  Betaseron,  Rebif,  Avonex,  Copaxone,  Extavia  and other  interferons 
and glatiramer acetate  
BUN Blood  Urea  Nitrogen  
CDP Clinical  Development  Plan 
CDS Core  Data  Sheet  
CK Creatinine  Kinase  
ClinRO  Clinician  Reported  Outcomes  
COA  Clinical  Outcome  Assessment  
CO2 carbon  dioxide  
CRF Case  Report/Record  Form  (paper  or electronic)  
CO Country  Organization  
CQA  Clinical  Quality  Assurance  
CRO  Contract  Research  Organization  
CDSGs  The Clinical  Development  Safety  Guidelines  
COPD  Chronic  Obstructive  Pulmonary  Disease  
CSR Clinical  study  report  
C-SSRS  Columbia  Suicide  Severity  Rating  Scale  
CTC Common  Terminology  Criteria  
CMO&PS  Chief  Medical  Office  and Patient  Safety  
CV coefficient  of variation  
DIN Drug  Inducted  Nephrotoxicity  
DLT Dose  Limiting  Toxicity  
DMC  Data  Monitoring  Committee  
DMT  Disease  Modifying  Therapy  
DS&E  Drug  Safety  and Epidemiology  
ECG  Electrocardiogram  
eCOA  Electronic  Clinical  Outcome  Assessment  
e-C-SSRS  Electronic  Columbia -Suicide  Severity  Rating  Scale  
EDC Electronic  Data  Capture  
EDSS  Expanded  Disability  Status  Scale  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  9  
Protocol  No. CBAF312AUS02   
 
 
ELISA  Enzyme -linked  immunosorbent  assay  
EOI End of Infusion  
EOS End of Study  
EOT/S  End of Treatment/Study  
eSource  Electronic  Source  
FDA Food  and Drug  Administration  
GCP  Good  Clinical  Practice  
GGT  Gamma -glutamyl  transferase  
H Hour  
HbsAg  Hepatitis  B surface  antigen  
HBV Hepatitis  B virus 
hCG Human  Chorionic  Gonadotropin  
HCP Healthcare  Professional  
HCV Hepatitis  C virus 
HEOR  Health  Economics  & Outcomes  Research  
HIV Human  immunodeficiency  virus 
HRQoL  Health -Related  Quality  of Life 
IB Investigator’s  Brochure  
ICF Informed  Consent  Form  
IMP Investigational  Medicinal  Product  
ICH International  Conference  on Harmonization  of Technical  Requirements 
for Registration of Pharmaceuticals for Human Use  
IEC Independent  Ethics  Committee  
INR International  Normalized  Ratio  
IRB Institutional  Review  Board  
IRT Interactive  Response  Technology  
i.v. intravenous  
  
LFT Liver  function  test 
LDH lactate  dehydrogenase  
LLOQ  lower  limit of quantification  
LLN lower  limit of normal  
MAP  Manage  Access  Program  
MedDRA  Medical  dictionary  for regulatory  activities  
mg milligram(s)  
ml milliliter(s)  
MS Multiple  Sclerosis  
MTD  Maximum  Tolerated  Dose  
Nab Neutralizing  antibody  
  
ObsRO  Observer  Reported  Outcomes  
Q.D. once  a day 
OCT 
PA Optical  Coherence  Tomography 
posteroanterior  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  10  
Protocol  No. CBAF312AUS02   
 
 
PC Personal Computer  
PD Pharmacodynamic(s)  
  
PerfO  Performance  Outcomes  
PK Pharmacokinetic(s)  
p.o. oral(ly)  
PRO  Patient  Reported  Outcomes  
  
QRS  Quantron  Resonance  System  
QTcF  QT interval  corrected  by Fridericia’s  formula  
PT prothrombin  time 
RAP/SAP  The Report  and Analysis  Plan (RAP)  is a regulatory  document  which 
documents preplanned statistical analyses  
RBC red blood  cell(s)  
RDE Recommended  dose  for expansion  
REB Research  Ethics  Board  
RECIST  Response  Evaluation  Criteria  In Solid  Tumors  
RMS  Relapsing  Multiple  Sclerosis  
RRMS  Relapsing -Remitting  Multiple  Sclerosis  
RP2D  Recommended  phase  two dose  
RU Resource  Utilization  
R Value  ALT/ALP  x ULN 
SAE Serious  Adverse  Event  
s.c. subcutaneous  
sCR serum  creatinine  
SD standard  deviation  
SDMT  Single  Digit Modality  Test 
SGOT  Serum  Glutamic  Oxaloacetic  Transaminase  
SGPT  Serum  Glutamic -Pyruvic  Transaminase  
SmPC  Summary  of Product  Characteristics  
SUSAR  Suspected  Unexpected  Serious  Adverse  Reactions  
TD Study  Treatment  Discontinuation  
TQSM -9 Treatment  Satisfaction  Questionnaire  for Medication  
ULN upper  limit of normal  
ULQ upper  limit of quantification  
WBC  white  blood  cell(s)  
WHO  World  Health  Organization  
WoC  Withdrawal  of Consent  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  11  
Protocol  No. CBAF312AUS02   
 
Glossary  of terms  
Additional  treatment  Medicinal  products  that may be used  during  the clinical  trial as described 
in the protocol, but not as an investigational medicinal product (e.g. any 
background therapy)  
Assessment  A procedure  used  to generate  data required  by the study  
Biologic  Samples  A biological  specimen  including,  for example,  blood  (plasma,  serum), 
saliva, tissue, urine, stool, etc. taken from a study patient  
Cohort  A specific  group  of patients  fulfilling  certain  criteria  and generally  treated 
at the same time  
Control  drug A study drug (active or placeb o) used as a comparator to reduce 
assessment  bias,  preserve  blinding  of investigational  drug,  assess 
internal study validity, and/or evaluate comparative effects of the 
investigational drug  
Cycles  Number  and timing  or recommended  repetitions  of therapy  are usually 
expressed as number of days (e.g., q28 days)  
Dosage  Dose  of the study  treatment  given  to the patient  in a time unit (e.g. 100 
mg once a day, 75 mg twice a day)  
Electronic  Data  Capture 
(EDC)  Electronic data capture (EDC) is the electronic acquisition of clinical 
study data using data collection systems, such as Web -based 
applications,  interactive  voice  response  systems  and clinical  laboratory 
interfaces. EDC includes the use of Electronic Case  Report Forms 
(eCRFs)  which  are used  to capture  data transcribed  from paper  source 
forms used at the point of care.  
End of the clinical  trial The end of the clinical  trial is defined  as the last visit of the last patient  or 
at a later point in time as defined by the protocol.  
Enrollment  Point/time  of patient  entry  into the study  at which  informed  consent  must 
be obtained  
eSource  (DDE)  eSource  Direct  Data  Entry  (DDE)  refers  to the capture  of clinical  study 
data electronically,  at the point  of care.  eSource  Platform/Applications 
reduce the use of paper capture source data during clinical visits. 
eSource  combines  source  documents  and case  report  forms  (eCRFs) 
into one application, allowing for the real time collect ion of clinical trial 
information  to Novartis  and other  oversight  authorities,  as appropriate.  
Healthy  volunteer  A person  with no known  significant  health  problems  who volunteers  to be 
a study participant  
Investigational 
drug/treatment  The drug whose  properties  are being  tested  in the study  
Medication  number  A unique  identifier  on the label  of medication  kits 
Mis-randomized 
patients  Mis-randomized patients are those who were not qualified for 
randomization  and who did not take study  treatment,  but have  been 
inadvertently randomized into the study  
Other  treatment  Treatment  that may be needed/allowed  during  the conduct  of the study  
(concomitant or rescue therapy)  
Part A sub -division of a study used to evaluate specific objectives or contain 
different  populations.  For example,  one study  could  contain  a single  dose 
part and a multiple do se part, or a part in patients with established 
disease and in those with newly -diagnosed disease.  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  12  
Protocol  No. CBAF312AUS02   
 
Patient  An individual  with the condition  of interest  for the study - 
Note:  use “patient”  in population  section  only,  use “patient”  in the rest of 
the document  
Period  The subdivisions of the trial design (e.g. Screening, Treatment, and 
Follow -up) which  are described  in the Protocol.  Periods  define  the study 
phases  and will be used  in clinical  trial database  setup  and eventually  in 
analysis  
Perpetrator  drug A drug which  affects  the pharmacokinetics  of the other  drug 
Premature  patient 
withdrawal  Point/time when the patient exits from the study prior to the planned 
completion  of all study  drug administration  and/or  assessments;  at this 
time all study drug administration is discontinued and no further 
assessments are planned  
Randomization  number  A unique  identifier  assigned  to each  randomized  patient  
Run-in Failure  A patient who is screened but not randomized/treated after the run -in 
period  (where  run-in period  requires  adjustment  to patient’s  intervention 
or treatment)  
Screen  Failure  A patient  who did not meet  one or more  criteria  that were  required  for 
participation in the study  
Source  Data/Document  Source data refers to the initial record, document, or primary location  
from where  data comes.  The data source  can be a database,  a dataset,  a 
spreadsheet or even hard -coded data, such as paper or eSource.  
Stage  in cancer  The extent  of a cancer  in the body.  Staging  is usually  based  on the size 
of the tumor, whether lymph nodes contain cancer, and whether the 
cancer has spread from the original site to other parts of the body  
Start  of the clinical  trial The start of the clinical  trial is defined  as the signature  of the informed 
consent by the first patient.  
Study  treatment  Any single  drug or combination  of drugs  or intervention  administered  to 
the patient as part of the required study procedures . 
Study  treatment 
discontinuation  When  the patient  permanently  stops  taking  any of the study  drug(s)  prior 
to the defined study treatment completion date (if any) for any reason; 
may or may not also be the point/time of study discontinuation  
Patient  A trial participant  (can be a healthy  volunteer  or a patient)  
Patient  number  A unique number assigned to each patient upon signing the informed 
consent.  This number  is the definitive,  unique  identifier  for the patient  and 
should be used to identify the patient throughout the study for all data 
collecte d, sample labels, etc.  
Treatment  arm/group  A treatment  arm/group  defines  the dose  and regimen  or the combination, 
and may consist of 1 or more cohorts.  
Variable  A measured  value  or assessed  response  that is determined  from specific 
assessments  and used  in data analysis  to evaluate  the drug being  tested 
in the study  
Victim  drug The drug that is affected  by the drug-drug interaction  
Withdrawal  of study 
consent  Withdrawal of consent is defined as when a patient does not want to 
participate  in the study  any longer,  and does  not want  any further  visits  or 
assessments, and does not want any further study related contact, and 
does not allow analysis of already collec ted biologic material.  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  13  
Protocol  No. CBAF312AUS02   
 
 
 
Amendment  05 
 
Rationale  for Amendment  
 
 
 
 
 
 
 
 
 
 
 
  
  
  
  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  14  
Protocol  No. CBAF312AUS02   
 
 
 
Amendment  04 
Rationale  for Amendment  
 
 
 
 
 
  
  
  
 
 
  
  
  
  
  
 
 
 
 
• Added  Section  4.6 to address  public  health  emergency  mitigation  procedures  
• Section  6.7.2  to enable  IMP home  delivery  of oral medication  directly  to a trial 
participant’s home rather than dispensed as part of an on -site study visit.  
• Updated  Section  7 to enab le remote  consent  
• Updated  Section  8 (including  sections  8.4 and 8.5) to enable  virtual  or phone  efficacy  and 
safety assessments or visits to the participant´s home, if possible, in the study, as well as 
remote COA data collection.  
• Updated  Section  11.4 Virtual  Patient  Cohort  to include  language  on mitigation 
procedures  for closure  of the virtual  patient  cohort  at discretion  of the sponsor.  
Amendment  4 removes  the enrollment  cap for Strata  1, referenced  in the Amendment  3 rationale 
section,  and allows patients with prior oral DMT (fumarates and teriflunomide) to continue to 
enroll.  Real-world  evidence  indicates  that the majority  of siponimod  patients  transitioning  from 
a prior DMT were most frequently taking another oral DMT (Shah et al, 2020 ). By lifting the 
enrollment cap for Strata 1, the amendment ensures that EXCHANGE generates clinical 
evidence that reflects real -world treatment paradigms and supports patients and providers.  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  15  
Protocol  No. CBAF312AUS02   
 
Additional interim analyses may be conducted at additional time points based on study 
enrollment under Amendment 4 to evalua te continued efficacy and safety data (for example, 
50% enrollment).  These interim analyses will allow for an evaluation of the infusion strata, 
which was incorporated with Amendment 3.  
Additional  changes  are listed  below:  
• Addition  of Vumerity®  (diroxime l fumarate)  and generic  forms  of dimethyl  fumarate 
changed in Inclusion Criteria and throughout  
• Added  interim  analysis  description  to Protocol  Summary , Section  4.4, and Section  
12.7 
• Added  language  for clarity  on ongoing  virtual  and traditional  cohorts  to Protocol  
Summary , Section 3 , and Section 4.1  
• Protocol Summary:  
• Correction  made  to Month  6 corresponding  Visit  number  (Visit  5) for first 
interim analysis  
• Updated  Study  Design  language  in Section  11.4 
• Table  8-1: Updated  table  as Hepatitis  screen  is only required  at Screening  
• Table  8-1: Correction  made  to footnote  #8 to reflect  correct  reference  section  in 
protocol  
• Section  4.4 and Section  12.7: Added  language  for conducting  additional  interim 
analyses  
• Section  8.4.4 : Updated  language  for guidance  on pregnancy  testing  
  
• Revised  Inclusion  Criteria:  
• #6: Addition  of Vumerity®  (diroximel  fumarate)  and generic  forms  of dimethyl 
fumarate  
• #7 removed  from  Protocol  Summary,  as this was not reflected  and consistent 
with the main protocol  
• Revised  Exclusion  Criteria:  
• #14: Added  clarifying  language  to described  history  of or current  significant 
cardiac disease  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  16  
Protocol  No. CBAF312AUS02   
 
Amendment  03 
Rationale  for amendment  
Amendment 3 broadens the pre -treatment groups to include natalizumab (an α 4-integrin 
antagonist, humanized monoclonal antibody) and ocrelizumab (a humanized monoclonal 
antibody that targets the CD20 marker on B -lymphocytes) infusion therapies in order to 
characterize the short term safety profile after conversion. The generation  of this data is 
important as it is expected that patients who are currently treated with natalizumab and/or 
ocrelizumab  may convert  to siponimod  for reasons  of safety,  tolerability,  effectiveness  or access. 
There are no known safety or tolerability concer ns with the co -administration of siponimod 
with natalizumab or ocrelizumab.  The purpose of broadening the pre -treatment groups is to 
further understand this relationship (Leurs et al., 2018 ); (Kappos et al., 2015 ). 
Sustained  fingolimod  induced  receptor  internalization  of S1P receptors  has been  demonstrated 
in a number  of separate  studies  (Jo et al., 2005 ); (Oo et al., 2007 ); (Mullershausen  et al., 2009 ); 
(Snelder et al., 2016 ). Both siponimod and fingolimod are sphingospine 1 -phosphate (S1P) 
receptor agonists causing complete internalization and down‐regulation  of the S1P1 receptor 
(Matloubian et  al., 2004 ); (Chiba et  al., 2006 ); (O’Sullivan et al., 2016 ); (Chun et al., 2010 ); 
(Subei and Cohen, 2015 ). It is postulated that the known immunomodulatory effect on 
lymphocytes and transient nature of the heart rate (HR) is most likely related to receptor 
internalization and degradation (Mullershausen et al., 2009 )). This downregulation renders 
lymphocytes unresponsive to the normal S1P gradient, and deprives them of the obligatory 
signal that would ordinarily allow them to egress from lymphoid tissues and recirculate to the 
periphery (Chun et al., 2010 ). Long -term suppression of receptors and minimized transient 
effects  on HR are maintained  by subsequent  regular  dosing  ( Brown  et al., 2019  ). Therefore, 
HR and atrioventricular (AV) conduction effects are not expected in patients 
converting from fingolimod therapy.  Thus, Amendment 3 will omit the need for 
siponimod  titration  regimen  for patients  converting  from  fingolimod  therapy  in order  to enhance 
understanding  of the role of titration,  or lack of, when  converting  between  the two S1P receptor 
modulators.  All study  patients  are dosed  under  the care of a healthcare  practitioner.  Fingolimod 
patients will receive an additional telephone call from site staff at the end of day 1 as part of 
additional safety measures.  
In order to ensure each pre -treatment strata in this st udy has a sufficient and balanced number 
of subjects  to assert  a clinically  meaningful  outcome,  a balanced  stratification  of 50 patients  per 
strata will be adopted, and therefore increasing the enrollment number to a maximum of 400 
patients.  
Lastly,  in an attempt  to help 1) remove  ambiguity,  2) clarify  the protocol  language  for principal 
investigators, 3) be consistent with siponimod label and or 4) account for the aforementioned 
changes,  revisions  to the exclusion  criteria  (including  adding  time or scenario  qualifiers),  study 
design graphic and other applicable supporting areas, were warranted.  Each  revised  section  is 
supported by applicable rationale as outlined in the details below.  
The purpose  for Amendment  03 is to: 
• Broaden  pre-treatment  groups  to include  infusion  disease  modifying  therapies, 
specifically, natalizumab and ocrelizumab.  
• Removal of titration regimen for patients converting from fingolimod treatment  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  17  
Protocol  No. CBAF312AUS02   
 
• Expand  study  n to 300 -400 patients  
• Revise  inclusion  criteria:  
• #6: Include  natalizumab and  ocrelizumab  to conversion options  
• Revise  exclusion  criteria:  
• #4 & #5: Move  post-menopausal  women  description  from  standalone  exclusion  and 
merge with existing pregnancy and contraception exclusion. The prior exclusion #5 
was merely  a description of women who are considered post -menopausal and not of 
child bearing potential and not a separate exclusionary criteria different from the 
pregna ncy exclusion.  
• #12: Delete natalizumab, daclizumab and ocrelizumab from prohibited list. 
Natalizumab  and ocrelizumab  will be added  to pre-treatment  groups  for inclusion; 
daclizumab is no longer commercially available.  
• #12: Added sub -criteria “more than 24 months prior treatment exposure to 
natalizumab”.  Based  on critical  assessment  of the limited  data available,  combined 
with the opinion of steering committee members, it is suggested that patients with 
more than 24 months of  prior natalizumab exposure may be at high risk for PML. 
Therefore, to minimize patient safety risks, added sub -bullet to exclusion #12.  
• #14: Added  time qualifier  to history  of cardiovascular  disease  consistent  with label 
“within last 6 months.”  
• #14: Added  therapeutic  disease  qualifier  to patients  receiving  treatment  with beta- 
blockers “for cardiac disease/comorbidities”  
• #17: Added  exception  to WBC  count  to include  “while  on injectable  or oral DMT’s 
at screening, except fingolimod” to reflect appropriate drop in WBC clinical lab 
values.  Exception for fingolimod added given the direct effect on peripheral 
lymphocyte subpopulations including WBCs.  
• #17: Added new sub -bullet “for patients previously exp osed to natalizumab, anti - 
JCV antibody  positive and index > 1.5.”  Based on critical assessment of the limited 
data available, combined with the opinion of steering committee members, it is 
suggested  that patients  with an anti-JCV antibody  index  >1.5 are considered  high risk 
for PML and therefore should be excluded if no MRI monitoring is part of the study 
design to help minimize risk of serious immunodeficiency.  
• Updated  study  design  figure  3-2. 
• Clarify:  
• Section  1.2: Added  identification  of clinical  gap and lack of data for conversion 
between S1P receptor modulators.  
• Section  1.2: Added  rationale  for broadening  pre-treatment  groups  to include 
natalizumab and ocrelizumab.  
• Section  2: Added  infusion  to treatment  options described  in primary  objective.  
• Section 3 : Added definition of “immediate conversion” to be “cessation of existing 
DMT  and initiation  of siponimod  within  24 hours,  followed  by subsequent  5-day dose 
titration.”  Additionally clarified teriflunomide treatment group will undergo 
accelerated elimination prior to initiating siponimod.  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  18  
Protocol  No. CBAF312AUS02   
 
• Section 3 : Added clarification that patients converting from fingolimod will not 
undergo  titration  period  and instead  immediately  start 2mg dose,  upon  completion  of 
required screening tests, including genotyping CYP2C9*1*1, as part of the 
inclusion/exclusion criteria.  
• Section 3 : Added clarification that patients converti ng from natalizumab will  
undergo  at least 4 week  washout  period  at time of consent  prior  to converting  to dose- 
titrated siponimod.  
• Section 3 : Added clarification that patients converting from ocrelizumab will 
undergo  at least 14 week  washout  period  at time of consent  prior  to converting  to 
dose-titrated siponimod.  
• Section  3, Figure  3-2: Updated  study  design  figure  to reflect  changes  in section 3. 
• Section  4.2: Added  rationale  for removal  of titration  regimen  for patients  converting 
from S1P receptor modulator, fingolimod.  
• Section  5: Clarified  functional  definition  of advancing  RMS  for purposes  of this 
study.  
• Section  5.1: Revised  inclusion  criteria  to include  infusion  therapy,  natalizumab  and 
ocrelizumab.  
• Section  5.2: Revised  exclusion  criteria  as described  above.  
• Section  6.1.3 : Clarifying  titration  language  to include  all patients  except  fingolimod 
group.  
• Section  6.2.1.1 : Clarifying  language  for patients  treated  with beta-blockers  for non- 
cardiac treatment purposes.  
• Section 6.2  Table:  Removal of prohibited medication criteria “any other 
immunomodulatory  of disease modifying MS treatment, including but not limited to, 
fingolimod, interferon beta, glatiramer acetate or systemic corticosteroids.”  This 
statement is incorrect because we are allowing fingolimod, interferon beta and 
glatiramer  acetate  in this study. Added  removal  of systemic  corticosteroids  as there  is 
no implication of this medication on patients in this study.  Prohibition of steroids is 
only required when conducting MRI to minimize confounding of post -lesion repair 
mechanisms.  
• Section  6.3.2 : Clarification  around  titration  regimen  for all patients  except  those 
converting from fingolimod.  
• Section  6.7.2 : Clarification  around  titration  regimen  for all patients  except  those 
converting from fingolimod.  
• Section  6.3 Table  6-3: Revised  table  header  to “Treatment  Schedule  for All Pre- 
Treatment groups except Fingolimod” and added separate dose and treatment 
schedule for fingolimod patients.  
• Section 8 : Added disease modifying therapy  washo ut regimen table and language for 
interferon -beta, dimethyl fumarate; accelerated elimination for teriflunomide; 
fingolimod;  natalizumab  and; ocrelizumab.  Clarification  language  regarding  pre-dose 
ECG, pre -dose HR, and post -dose HR collection methods.  
• Section  8 Table  8-1: Added  CD19+  B-cell titer at Screening  only to support  B-cell 
regeneration kinetic insights during conversion to siponimod.  Added footnote  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  19  
Protocol  No. CBAF312AUS02   
 
reflecting  this is only needed  for patients  converting  from  ocrelizumab  as that is the 
only B -cell therapy being introduced in this study.  
• Section  8.4.1  Table  8-3: Added  CD19+  titers  to “additional  tests”  subsection.  
• Section 8.4.3 : Added clarifying language that the OCT test can be performed by 
referred  ophthalmologist  or clinically  trained  neurologist  with expertise  in assessing 
structural measurement of retinal nerve fiber layer thickness, optic nerve head and 
macular anatomy and is in possession of appropriate OCT equipment in -office.  
• Section  12.4: Added  clarifying  language  related  to the primary  objective.  
• Section  12.8.1 : Added  revised  language  regarding  sample  size, precision  estimates 
and infusion therapy n. in order to achieve balanced stratification.  
• Appendix  16.6: Added  clarifying  guidance  around  accelerated  elimination  program 
for patients converting from teriflunomide.  
• Appendix  16.8: Corrected  Visit  3 to Visit  4 and added  clarifying  language  regarding 
OCT as described in section 8.4.3 . 
• Additional  changes  are listed  below:  
• Correction of “Siponimod” to lower case “siponimod throughout protocol.  
• Ensure  CYP2C9  is marked  in full form  and not abbreviated.  
• Replacement  of investigational  compound  name  BAF312  to brand -name,  Mayzent  ® 
throughout protocol.  
• Minor  clarifications  to background  introduction.  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  20  
Protocol  No. CBAF312AUS02   
 
Amendment  02 
Rationale  for amendment  
The purpose  for Amendment  02 is to: 
• Revised  exclusion criteria #22 to also exclude CYP2C9*2/*3 and CYP2C9*1/*3 patients:  
• Genetic polymorphisms of the CYP2C9 enzyme are a major determinant of the inter - 
individual variability in the dosage requirements of siponimod. Per the Mayzent 
approved US Pack age Insert, Mayzent® is contraindicated in patients who have a 
CYP2C9*3/*3 genotype because of substantially elevated siponimod plasma levels. 
MAYZENT dosage adjustment to 1 mg is recommended in patients with 
CYP2C9*1/*3 or *2/*3 genotype because of an inc rease in exposure to siponimod. 
However, due to the current unavailability of a 1mg dosage form for Mayzent, 
patients with the CYP2C9*1/*3 and *2/*3 genotypes are dosed using the 0.25mg 
tablets  (4 x 0.25mg  = 1mg).  Novartis  will exclude  the CYP2C9*3/*3,  CYP 2C9*2/*3, 
and CYP*1/*3 patients from the CBAF312AUS02 study  and will only enroll patients 
who after titration, will take the 2mg recommended maintenance dose (CYP2C9 
Genotypes *1/*1, *1/*2, or *2/*2).  
• Revised  ECG  interval  values  to reflect  PR interval:  >200 msec;  QRS  duration  ≥120 msec; 
QTcF >430 msec (males); QTcF >450 msec (females)  
• Revised  Exclusion  #23: Concomitant  use of MAYZENT  and drugs  that cause  moderate 
CYP2C9 and moderate or strong CYP3A4 inhibition (Appendix 4).  
• Added  exclusion  #24: Concomitant  use of MAYZENT  and drugs  that cause  moderate 
CYP2C9 and strong CYP3A4 induction (Appendix 4).  
• Added  exclusion  #25: Use of cannabinoid  or cannabidiol  products  30 days prior  to 
screening.  
a. At this time, there is no evidence of combination treatment with cannabinoid or 
cannabidiol  products  and siponimod.  Thus,  for patients’  safety,  the concomitant  use 
of these products will be excluded from the study.  
• Removed  Visit 2/Day  7 (in office/home visit)  
a. In line with the approved  US package  insert  for Mayzent,  Novartis  removes  the Day 7 
pre-dose ECG.  
• Under  Figure  3-1: Removed  the managed  access  program  and updated  language  for 
patient services hub for post -trial. 
 
Additional  changes  are listed  below:  
• Exclusion  criteria  Note  2: Updated  to reflect  that each patient  may be rescreened  no more 
than 1 time.  
• Section  4.4 and Section12.7 : Update  visit number  from  Visit  3 (Day  28) to Month  6 (Visit 
5/Day 168).  
• Section  8 Table  8-1 Assessment  Schedule:  Grayed  out Visit  2 (Day  7) not to be 
performed.  
• Removed  footnote #4  (12 Hour  fasted food samples).  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  21  
Protocol  No. CBAF312AUS02   
 
• Added  language  to footnote  # 
• Section  8, Table  8-3 physical  examination  and neurological  exam  language  was updated.  
• Section  8.4.1  Laboratory  Evaluations  under  CYP2CP  testing  language  was updated.  
• Section  8.4.2  Electrocardiogram  language  was updated.  
• Sections  8, 10.2.2  and 16.7 (Appendix  7): Revision  of pre-dose (< 55bpm)  and post-dose 
(<45 bpm) bradycardia definition to be consistent throughout protocol.  
• Section  15: Added  references.  
• Section  16.4: Updated  Appendix  4. 
 
All relevant  section(s)  of the protocol  are updated  to reflect  the update  in the exclusion  criteria 
and removal of Day 7 pre -dose ECG.  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  22  
Protocol  No. CBAF312AUS02   
 
Amendment  01 
Rationale  for amendment  
 
The purpose  for Amendment  01 is to update  all relevant  section(s)  of the protocol  related  to: 
• Drug  supply,  reflecting  the details  of how the drug is supplied  and will be provided  in a 
pharmacy manual.  
• Additional  cardiac  monitoring  for Day 1 and Day  7 prior  to treatment  
• The addition  of ophthalmic  assessment  (optical  coherence  tomography;  OCT)  at Day 1 
(baseline) and Day 84 for incidences of macular edema.  
 
Additional  changes  are listed  below:  
• Table  2-1: Removed  CSSRS  from  exploratory  objectives.  
• Section  5.2 – Updated  Exclusion  criteria  #15 to be aligned  with definition  of high-risk 
cardiac patients in the CBAF312A2304 study.  
• Section  6.1.1 : 
a. Added  a requirement  of restarting  titration,  if a day or more  of the 5-day titration  is 
missed.  
b. Added  that a pharmacy  manual  will be provided,  with specific  instructions,  regarding 
study drug, titration and maintenance dose.  
c. Added sentence: “If the patient has missed greater than 30 consecutive days of 
treatment,  using  his/her best medical  judgement,  the PI should  consider  terminating 
the patient from the study.”  
• Section  6.5: Added  “Siponimod  dose adjustments  are not permitted.”  
• Section  6.7: Added  that supply  of siponimod  will be described  in pharmacy  manual.  
• Section  6.7.2 : Added  that sites should  refer to pharmacy  manual  for specific  instructions 
on preparation and dispensation of study treatment.  
• Section  8: Updated  language  in first bullet  regarding  assessment  of vitals  and heart  rate at 
Visit 1 (Day 1).  
• Table  8-1: 
a. Added  visit windows  (±days)  for each clinical  visit 
b. Updated  visit names  and numbering,  as well as added  heart  rate assessment  (pre-dose) 
at baseline visit.  
c. Updated  height  assessment,  from  being  performed  at every  visit,  to just done  at 
screening and EOT/S visits.  
d. Included  OCT assessment at  Day 1 (baseline)  and Day 84. 
e. Included  ECG  assessments  at screening,  Day 1 (baseline)  pre-dose,  and Day 7 pre- 
dose.  
• Section  8.4.2 : provided  detailed  direction  on when  to obtain  ECG  assessment  (Day  1 and 
Day 7; pre -dose).  Further, provided instructions should the patient be at cardiac risk.  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  23  
Protocol  No. CBAF312AUS02   
 
• Section 8.4.5 : We included the use of OCT as part of ophthalmologic assessments at 
baseline  prior  to siponimod  treatment  and on Day 84 (3 months  post initial  treatment  with 
siponimod.  The purpose of this assessment is to monitor incidences of macular edema in 
patients treated with siponimod.  This inclusion can be found in the Table of Assessment 
(Table 8 -1; Section 8.4.5  and Appendix 8 ) 
• Section  10.2.2 : Updated  C-SSRS  language  including  clarification  regarding  the method  in 
which it will be administered.  
• Section10.2.2 : Added  bradycardia  as an adverse  event  of special  interest  
• Added  Section  11.4: Potential  Remote  Patient  Cohort.  (These  are patients  who would 
potentially  be allowed to participate, in the study, remotely, via online technology and 
telemedicine).  
• Section  12.5.1 : Added  language  that change  in heart  rate (and other  vitals),  from  baseline 
to 6-hours post dose, may be summarized in secondary endpoint analysis.  
• Section  12.7: Updated  language  to state that: an interim  analysis  on the safety  data will be 
conducted at the time of approximately 50 patients completing Visit 3 (Day 28).  
• Section  12.8.1 : Updated  language  to state that: A sample  size of 300 patients  will provide 
us the precision (half -width of 95% confidence interval) of 5.6%.  
• Section  16.7: Included  treatment  management  for bradycardia.  
• Section  16.8: Include  guidelines  for ophthalmic  examination  and management  of macular 
edema  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  24  
Protocol  No. CBAF312AUS02   
 
Protocol  summary  
 
 
Protocol  number  CBAF312AUS02  
Full Title Exploring  the safety  and tolerability  of conversion  from oral 
injectable or infusion disease modifying therapies to dose - 
titrated  Oral Siponimod  in patients  with advancing  forms  of 
relapsing multiple sclerosis: A 6 -month open label, multi - 
center Phase IIIb study (EXCHANGE)  
Brief  title Study of the safety and tolerability dose -titrated Oral 
Siponimod  in patients  with relapsing  forms  of multiple 
sclerosis.  
Sponsor  and Clinical  Phase Novartis  
Clinical  Phase  IIIb 
Investigation  type Drug  
Study  type Interventional,  Open -label 
Purpose  and rationale  The purpose of this study is to assess early phase safety and 
tolerability of converting patients from approved oral, 
injectable  or infusion  RMS  DMTs  to siponimod.  The results  of 
this study will guide clinically relevant decisions related to the 
transition  from frequently used RMS DMTs to siponimod and 
provide clinically relevant data on safety and tolerability for 
healthcare providers who are considering converting patients 
from currently approved RMS DMT to siponimod.  
Primary  Objective(s)  The primary objective is to evaluate overall safety and 
tolerability profile of siponimod in advancing RMS patients 
(including  a broader  population  that had not been  previously 
studied with siponimod who are converting from currently 
approved oral, injecta ble or infusion RMS DMT).  
Secondary  Objectives  • Objective  1: To evaluate  treatment  satisfaction  outcomes 
using the Treatment Satisfaction Questionnaire for 
Medication (TSQM -9) with siponimod in advancing RMS 
patients.  
• Objective  2: To evaluate  cardiac  safety,  in the overall 
population during siponimod treatment initiation  
• Objective  3: To evaluate  treatment  adherence  with 
siponimod.  
Study  design  This is a 6 -month, open -label, multi -center, single treatment 
arm design, including 300 -400 advancing RMS patients, 
evaluating overall safety and tolerability profile when acutely 
converting to siponimod from oral, injectable or infusion RMS 
DMT. This stud y consists of two parts: The Screening Period 
and Core  Treatment  Period,  plus a 30-day follow -up telephone 
call. 
 
 
 
 
 
 

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  25  
Protocol  No. CBAF312AUS02   
 
  
 
 
 
 
 
Population  The study population will consist of out -patient, male and 
female patients, ≥18-65 years of age, with an EDSS score > 
2.0-6.5 with advancing RMS with or without progressive 
features.  Approximately 300 -400 patients will be enrolled in 
this study from up to 80 study sites in the USA.  The study 
plans  to screen  approximately  570 patients.   
 
 
Key Inclusion  criteria  Patients  eligible  for inclusion  in this study  must  meet  all of the 
following criteria:  
1. Signed  informed  consent  must  be obtained  prior to 
participation in the study.  
2. Male  or female  aged  18 to 65 years  (inclusive)  at 
screening  
3. Patients  with advancing  RMS  as defined  by the principal 
investigator  
4. Prior history of relapsing MS (RMS), with or without 
progressive  features,  according  to the 2010  Revised 
McDonald or Lublin criteria (Lublin et al, 2013 ) 
5. Disability  status  at screening  with an EDSS  score  of >2.0 
to 6.5 (inclusive)  
6. Having been continuously treated with beta -interferons, 
glatiramer  acetate,  fingolimod,  fumarates,  teriflunomide, 
natalizumab or ocrelizumab for at least 3 months at the 
time o f consent  
7. Patients desiring to start treatment with a DMT 
investigated  in advancing  stages  of multiple  sclerosis.  
Key Exclusion  criteria  Patients  meeting  any of the following  criteria  are not eligible  for 
inclusion  in this study.  No additional  exclusions  may be applied 
by the investigator in order to ensure that the study  population 
will be representative of all eligible patients:  
1. Patients with an active chronic disease (or stable but 
treated  with immune  therapy)  of the immune  system  other 
than MS (e.g., rheumatoid arthritis, scleroderma, 
Sjogren’s syndrome, Crohn’s disease, ulcerative colitis, 
etc.) or with a known immunodeficiency syndrome (AIDS, 
hereditary immune deficiency, drug -induced immune 
deficiency).  
2. Pregnant  or nursing  (lactating)  women,  where  pregnancy 
is defined as the state of a female after conception and 
until the termination of gestation, confirmed by a positive 
hCG laboratory test.  
3. Women  of child-bearing  potential,  defined  as all women 
physiological ly capable of becoming pregnant, unless  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  26  
Protocol  No. CBAF312AUS02   
 
 they are using highly effective methods of contraception 
while  taking  study  treatment  and for 30 days  (30 = 5 times 
the terminal half -life of siponimod) after stopping study 
treatment.  Highly  effective  contraception  methods  include:  
• Total abstinence (when this is in line with the 
preferred and usual lifestyle of the patient. Periodic 
abstinence  (e.g.,  calendar,  ovulation,  symptothermal, 
post-ovulation methods) and withdrawal are not 
acceptable methods of contraception  
• Female sterilization (have had surgical bilateral 
oophorectomy with or without hysterectomy), total 
hysterectomy, or tubal ligation at least six weeks 
before taking study treatment. In case of 
oophorectomy alone, only when the reproductive 
status  of the woman  has been  confirmed  by follow  up 
hormone level assessment  
• Male sterilization (at least 6 months prior to 
screening).  For female  patients  on the study,  the 
vasectomized male partner should be the sole 
partner for that patient  
• Use of oral, (estrogen  and progesterone),  injected  or 
implanted hormonal methods of con traception or 
placement of an intrauterine device (IUD) or 
intrauterine  system  (IUS),  or other  forms  of hormonal 
contraception that have comparable efficacy (failure 
rate <1%), for example hormone vaginal ring or 
transdermal hormone contraception.  
In case of use of oral contraception women should 
have  been  stable  on the same  pill for a minimum  of 3 
months before taking study treatment.  
• Women are considered post -menopausal and not of 
child bearing potential if they have had 12 months of 
natural (spontaneous) amenorrhea with an 
appropriate clinical profile (e.g. age appropriate  
history of vasomotor symptoms) or have had surgical 
bilateral  oophorectomy  (with  or without  hysterectomy), 
total hysterectomy or tubal ligation at least six weeks 
ago. In the case of oophorectomy alone, only when 
the reproductive status of the woman has been 
confirmed by follow up hormone level assessment is 
she cons idered not of child bearing potential.  
4. Sexually active males unwilling to use a condom during 
intercourse while taking study treatment and for 30 days 
(30 days  = 5 times  the terminal  half-life of siponimod)  after 
stopping stud y treatment. A condom is required for all 
sexually active male participants to prevent them from 
fathering a child AND to prevent delivery of study 
treatment via seminal fluid to their partner. In addition, 
male participants must not donate sperm for the t ime 
period specified above.  
If local regulations deviate from the contraception 
methods listed above to prevent pregnancy, local 
regulations  apply  and will be described  in the ICF. 

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  27  
Protocol  No. CBAF312AUS02   
 
 5. History of malignancy of any organ system (other  than 
localized basal cell carcinoma of the skin), treated or 
untreated,  within  the past 5 years,  regardless  of whether 
there is evidence of local recurrence or metastases.  
6. Diabetes mellitus, unless well c ontrolled and without 
known organ complications including but not limited to 
heart  disease,  reduced  renal  function,  significant  retinal 
pathology or neuropathy.  
7. Diagnosis  of macular  edema  1 year prior to screening.  
8. Patients with active systemic bacterial, viral, or fungal 
infections  or known  to have  AIDS  or have  positive  HIV 
antibody.  
9. Positive  results  of screening  period  testing  for serological 
markers for hepatitis A, B, C and E, indicating acute or 
chronic infec tion: 
• anti-HAV IgM 
• HBs Ag and/or  anti-HBc IgM 
• anti-HEV IgM (if positive  IgG and/or  IgM, perform 
HEV-RNA PCR and if negative, patient can be 
included).  
Note:  If the treating  physician  suspects  false  positive  hepatitis 
serology results, such as an antibody pattern indicating acute 
hepatitis  infection  but no corresponding  elevated  liver enzymes 
and no signs or symptoms of liver disease, a HEV -RNA PCR 
will be performed and will be the deciding factor to determine 
whether  the patient  has hepatitis  A, B, C, or E. If negative,  the 
treating  physician  may document  (in source  data and in a eCRF 
comment) that the serology results are considered false 
positive and consider including the patient.  
 
10. Negative for varicella -zoster virus IgG antibodies at 
Screening unless there is other evidence of immunity to 
VZV based on the CDC criteria 
(https://www.cdc.gov/chickenpox/hcp/immunity.html ; see 
Appendix 1 ) 
11. Have received any live or live -attenuated vaccines 
(including  for varicella -zoster  virus  or measles)  within  2 
months of screening.  
12. Have  been  treated  with any of the medi cations  listed 
below:  
• Intravenous  immunoglobulin  within  2 months  prior to 
screening  
• Immunosuppressive/chemotherapeutic  medications 
(e.g., azathioprine, methotrexate) within 6 months 
prior to screening  
• Cyclophosphamide  within  2 years  prior to screening  
• More  than 24 months  prior treatment  exposure  to 
natalizumab  
• Rituximab,  ofatumumab,  ublituximab  or cladribine 
within 2 years prior to randomization  
• Alemtuzumab  at any time 

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  28  
Protocol  No. CBAF312AUS02   
 
 • Any mitoxantrone during previous 2 years prior to 
randomization  or evidence  of cardiotoxicity  following 
mitoxantrone or a cumulative life -time dose of more 
than 60 mg/m2  
• If patients  treated  with teriflunomide  cannot  or will not 
undergo the accelerated elimination process 
(Appendix 6 ) 
• Stem  cell transplantation  
• Lymphoid  irradiation,  bone  marrow  transplantation  or 
other immunosuppressive treatments with effects 
potentially lasting over 6 months, at any time.  
 
13. Patients  with any medically  unstable  condition  as 
determine by the investigator.  
 
14. Any of the following  conditions  or treatments  that may 
affect cardiovascular function within last 6 months:  
• Heart  rate < 55 bpm at screening  
• Cardiac  conduction  disorders  such  as incomplete  left 
bundle branch block or second degree AV block 
Mobitz type I (Mobitz I) (either history or observed at 
screeni ng) 
• Minor  ECG  findings  at screening  PR interval:  >200 
msec;  QRS  duration  ≥120 msec;  QTcF  >430  msec 
(males); QTcF >450 msec (females)  
• History of or current significant cardiac disease 
including  cardiac  failure  (NYHA  functional  class  II-IV), 
myocarditis, cardiomyopathy, angina pectoris or  
myocardial  infarction  (within  6 months),  unstable  
angina (within 6 months), stroke (within 6 months), 
TIA (within  6 months),  decompensated  heart  failure 
requiring hospitalization (within 6 months) or 
uncontrolled arterial hypertension  
• Patients  receiving  treatment  with beta-blockers  for 
cardiac disease/comorbidities.  
• Any other condition which, in the opinion of the 
investigator, has a potential for AV conduction 
suppression  and/or  other  risk factors  that may require 
expanded cardiac monitoring  
• Patients  diagnosed  with right bundle  branch  block, 
either  at the screening  visit for entry  of the study  or 
during the conduct of the study  
 
15. Any of the following  pulmonary  conditions:  
• History  of or active  severe  respiratory  disease, 
including COPD, or pulmonary fibrosis,  
• Tuberculosis,  except  for history  of successfully 
treated  tuberculosis  or a history  of prophylactic 
treatment after positive PPD skin reaction  
• Patient  with severe  asthma  or asthma  requiring 
regular treatment with oral steroids  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  29  
Protocol  No. CBAF312AUS02   
 
  
16. Patients  with any of the following  hepatic  conditions  prior 
to screening:  
• history  of alcohol  abuse,  chronic  liver or biliary 
disease  
• total or conjugated  bilirubin  greater  than 1.5 times 
ULN range, unless in the context of Gilbert’s 
syndrome  
• alkaline  phosphatase  (AP) greater  than 1.5 times  the 
ULN range  
• AST (SCOT),  ALT (SGPT)  or Gamma -glutamyl - 
transferase  (GGT)  greater  than 3 times  the ULN 
range within the last 6 months  
 
17. Any of the following  abnormal  laboratory  values  prior to 
screening:  
• Serum  creatinine  > 1.7 mg/dL  (150 umol/L)  
• White  blood  cells (WBC)  count  <3,500/mm3  (<3.5  x 
10(9)/L), while on injectable or oral DMT’s at 
screening, except fingolimod  
• Lymphocyte  count  <500/mm3  (<0.5  x 10(9)/L)  while 
on all DMT’ s at screening except fingolimod  
• Serum  potassium  > ULN 
• Or other  clinically  significant  laboratory  assessment 
(i.e. hypomagnesemia or hypokalemia)  
• For patients  previously  exposed  to natalizumab,  anti- 
JCV antibody positive and index  > 1.5 
 
18. Patients  with the following  neurological/psychiatric 
disorders prior to screening:  
• History  of substance  abuse  (drug  or alcohol)  or any 
other factor (i.e. serious psychiatric condition) that 
may interfere with the patient’s ability to cooperate 
and comply  with the study protocol  
• Progressive neurological disorder, other than MS, 
which  may affect  participation  in the study  or require 
the use of medications not allowed by the protocol  
 
19. Use of other  investigational  drugs  at the time of enrollment 
or within prior 30 days; or five elimination half -lives, or  
until the expected pharmacodynamics effect has returned 
to baseline, whichever is longer.  
20. History  of hypersensitivity  to the study  drug or to drugs  of 
similar chemical classes.  
21. Homozygosity  for CYP2C9*3/*3  or heterozygous  for 
CYP2C9*2/*3 or CYP2C9*1/*3  (to be tested at 
screening) or refusal to test for CYP2C9 variants.  
22. Concomitant  use of MAYZENT  and drugs  that cause  
moderate  CYP2C9  and moderate  or strong  CYP3A4 
inhibition ( Appendix 4 ). 

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  30  
Protocol  No. CBAF312AUS02   
 
 23. Concomitant  use of MAYZENT  and drugs  that cause 
moderate CYP2C9 and strong CYP3A4 induction 
(Appendix 4 ). 
24. Use of cannabinoid  or cannabidiol  products  30 days  prior 
to screening.  
25. Any other  disease  or condition,  which  could  interfere  with 
participation in the study according to the study protocol, 
or with the ability  of the patients  to cooperate  and comply 
with the study procedures.  
Note 1:  If a patient fails on one or more laboratory (or other) 
assessment criteria, as part of the screening process, the 
assessment (s) may be repeated at the discretion of the 
investigator  and the patient  may be included  if criteria  are then 
met, provided the a ssessments are completed within the 
screening period.  
Note 2:  In certain cases rescreening of patients that were 
previously determined ineligible may be permitted.  When a 
patient is re -screened, a new patient identification number will 
be assigned  and all screening  assessments  must  be repeated. 
Each patient may be rescreened no more than one time.  
 
No additional  exclusions  may be applied  by the investigator,  in 
order  to ensure  that the study  population  will be representative 
of all eligible patients.  
Study  treatment  All eligible  patients  will receive  oral siponimod  (Mayzent  ®). 
The study treatment will be provided for the duration of the 
trial from baseline  (Day  1) through  last day of the treatment 
period.  
Efficacy  assessments   
 
  
 
 
  
 
  
 
Key safety  assessments  Physical  examinations  
Monitoring  of laboratory  markers  in blood  (plasma/serum) 
Monitoring of macular edema through the use of OCT 
Electrocardiogram (ECG)  
Adverse  event  monitoring  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  31  
Protocol  No. CBAF312AUS02   
 
Other  assessments  An assessment  of Patient  reported  outcomes  is planned  in this 
trial using  Patient reported 
outcomes (PRO)  
Data  analysis  The primary  aim of this study  is to evaluate  the overall  safety 
and tolerability profile of siponimod 2 mg in patients with 
relapsing forms of MS.  
The number (and percentage) of  patients with treatment 
emergent adverse events suspected to be related to study 
medication  will be summarized  by primary  system  organ  class 
and preferred term. The 95% confidence interval for the 
overall rate of adverse event suspected to be related to s tudy 
medication will be calculated.  
A patient with multiple adverse events within a category 
(overall,  primary  system  organ  class,  or preferred  term)  is only 
counted once towards the total of that category.  
The above  analyses  will be conducted  on the Safety  Set. For 
the purpose of earlier dissemination, an interim analysis on 
the safety  data will be conducted  at the time of approximately 
50 patients will complete their Month 6 (visit 5). Additional 
interim analyses may be conducted at additional time p oints 
based on study enrollment in order to evaluate continued 
efficacy and safety data (for example, 50% enrollment).  
These  interim  analyses  will also allow  for an evaluation  of the 
infusion strata.  
 
 
 
 
Key words  Siponimod,  Disease  Modifying  Therapy  , Multiple  Sclerosis, 
Relapsing Multiple Sclerosis, Relapsing -Remitting Multiple 
Sclerosis, Secondary Progressive MS  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  32  
Protocol  No. CBAF312AUS02   
 
1 Introduction  
1.1 Background  
Multiple Sclerosis (MS) is an immune -mediated disease of the central nervous system (CNS) 
characterized by inflammation, demyelination and axonal/neuronal destruction, ultimately 
leading  to severe  disability.  It affects  approximately  2.5 million  individual s worldwide  and has 
distinct clinical stages including relapsing remitting MS (RRMS), secondary progressive MS 
(SPMS)  and primary  progressive  MS (PPMS).  At the time of diagnosis,  approximately  85% of 
patie nts have recurrent, acute relapses of neurological symptoms.  More than 50% of patients 
with poorly treated RRMS transition to secondary progressive disease within 15 -20 years 
(Tremlett et al, 2008 ). In progressive stages, relapses are absent or infrequent, yet disability 
continues to gradually worsen (MS Society, accessed 2 018). 
The McDonald Criteria (McDonald et al, 2001 ) was the first diagnostic criteria for MS to 
employ MRI measures alongside of clinical assessments.  As more data and experience with 
MRI  were  acquired  (Tintore  et al. 2000 ; Swanton  et al. 2006,  2007 ; Montalban  et al. 2010) ) the 
criteria evolved further with two subsequent revisions (Polman et al 2005, 2011 ). Currently, 
the 2010  revision  of the McDonald  Criteria  is utilized  to characterize  the patients’  clinical  stage 
and determine the patients’ eligibility to participa te in the trial.  
Currently, approved disease modifying therapies (DMTs) are indicated for use in relapsing 
forms  of MS (RMS)  in the USA.  RMS  includes  RRMS  and SPMS  patients  with superimposed 
relapses.  The effec t of drug in these SPMS patients is presumed to have increased effect on 
inflammatory activities (relapses and gadolinium enhancing lesions), efficacy on disability 
progression  has not been  confirmed  in secondary  progressive  patients.  Mitoxantrone  is the only 
therapy  approved  for reducing  neurologic  disability  and/or  the frequency  of clinical  relapses  in 
patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing - 
remitting multiple sclerosis (i.e., patients whose neurologic  status is significantly abnormal 
between relapses) in the USA.  However, data demonstrating the efficacy of mitoxantrone in 
SPMS patients (Goodin et al, 2002 ) and the risks associated with mitoxantrone (heart failure, 
leukemia) limits its use.  
Sphingosine -1-phosphate (S1P) receptor modulators possess a unique mechanism of action in 
the treatment of relapsing and progressive MS (Gergely et al, 2012 ). The S1P1 and S1P5 
receptors are commonly found on the surface of astrocytes and oligodendrocytes, residing in 
the CNS,  and are potentially  implicated  in mechanisms  affecting  CNS  repair  (O’Sullivan  et al. 
2016 ). Siponimod (Mayzent®), approved by the US FDA in March 2019 for treatment of 
relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing 
remitting diseas e and active secondary  progressive disease in adults, is a S1P1/S1P5 -selective 
agonist.  It has  scientific  evidence  for involvement  with reducing  T-cell migration  to the CNS, 
astrogliosis,  oligodendrocyte process  modulation  and increased cell  survival (Chiba  et al, 2012 ); 
(Sanna et al, 2004 ). The mechanism of action on immune cells is similar to the first -in-class 
drug, fingolimod, with S1P1 -mediated trapping of lymphocytes in the peripheral lymphatic 
tissues . Siponimod,  however,  has a different  chemotype  than fingolimod,  as it is not a prodrug 
and thus does not require a phosphorylation step in vivo . It readily crosses the blood -brain - 
barrier (BBB), and preclinical studies suggest: it may prevent synaptic neurodegeneration 
(Gentile  et al, 2016 ); increases  levels  of myelin  basic  protein;  promotes  remyelination;  and 

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  33  
Protocol  No. CBAF312AUS02   
 
activates pERK and pAKT signaling to promote internalization of S1P1 receptors to a greater 
extent  (O’Sullivan  et al, 2016 ) than S1P itself  (Gentile  et al, 2016 ); (O’Sullivan  et al, 2016 ). In- 
vitro studies sho w that by binding to these specific receptors, siponimod may prevent the 
activation of these cells, helping to reduce loss of physical and cognitive function associated 
with MS (Aslanis et al, 2012). ) 
Next  to its effects  in lymphocyte  trafficking  and trapping  in peripheral  lymphatic  tissue  (similar 
to fingolimod), expression of S1P1 receptor ligands in atrial, septal and ventricular cardiac 
myocytes (as well as en dothelial cells of cardiac vessels in humans) has been established and 
associated  with the regulation  of heart  rate (HR)  at treatment  initiation  in both healthy  patients 
and in MS patients.  
The half -life of siponimod compared to fingolimod is shorter (approximately 30 h versus 200 
h), therefore drug effects cease more rapidly after discontinuation.  90% Recovery of the 
baseline lymphocyte counts after treatment withdrawal from steady  state condi tions should be 
achieved  in one week  at a daily  siponimod  dose of 2mg.  However,  residual  pharmacodynamics 
effects, such as lowering effects on peripheral lymphocyte count may persist for up to 3 to 4 
weeks  after the last dose.  Use of immunosuppressants  within this period  may lead to an additive 
effect  on the immune  system  and therefore  caution  should  be applied  3 to 4 weeks  after the last 
dose.  
The siponimod receptor selectivity  and half -life has the potential to enable full efficacy  in MS 
without  targeting  other  S1P receptors  (S1P3  and/or  S1P4),  which  together  with the more  rapid 
washout may improve the safety profile.  
The Phase  I clinical  pharmacology  trials,  siponimod  was safe and generally  well tolerated.  The 
study detected a dose dependent bradyarrhythmic effect within 2 -3 hours after intake of first 
dose.  
A placebo -controlled Phase II study in patients (N=297) with RRMS was conducted to 
determine  the dose-response  curve  for the MRI -based  efficacy  of siponimod,  and to characterize 
its safety  and tolerability  (Selmaj  et al 2013 ). A significant  dose response  relationship  at Month 
3 was observed  (p=0.0001,  Emax  model).  Siponimod  treatment  reduced  the combined  unique 
active lesion (CUAL) count by up to 80% vs. placebo, with the 2mg dose providing near - 
maximal  efficacy.  Annualized  relapse  rates  (ARR) were  0.61,  0.20 and 0.30 for the 0.5, 2 and 
10mg doses, respectively, vs 0.58 for placebo (p<0.05 for 2mg vs. placebo only).  
• Five transient  symptomatic  bradyarrhythmic  events  without  sequelae  were  observed  with 
the two highest doses.  
• Other safety findings included liver enzyme elevation (4.3% of patients at higher dose 
levels  had transaminases  >3x upper  limit  normal  (ULN)  and one case of macular  edema  in 
a patient with history of uveitis.  
• Serious  adverse  events  (SAEs)  included  one death (27 days post study  drug 
discontinuation), likely due to coronary artery disease.  
Due to the occurrence  of bradyarrhythmic  events  during  in the Phase  I trial, a dose titration  was 
implemented in the Phase  II study,  resulting  in the attenuation  of the earlier  observed  negative 
chronotropic and dromotropic  effects.  There  were  no symptomatic  bradyarrhythmic events or 
asymptomatic AV -blocks of concern following the introduction of the initial -dose titration 
scheme.  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  34  
Protocol  No. CBAF312AUS02   
 
The double -blind  registration  Phase  III EXPAND trial, (N=1651) demonstrated  unique  effects 
on SPMS  patients  (Kappos  et al, 2018 ). The majority  of the study  population  had been  on other 
DMTs prior to entering into the study.  In patients randomized to the siponimod arm, 
approximately 69% of patients had previously been treated with either IFNβ -1a or IFNβ -1b 
while 26% of patients had been treated with glatiramer acetate.  For patients on prior DMTs, 
there were specific washout re quirements implemented without any monitoring during the 
washout.  Given  the development  of additional  S1P receptor  modulators  over the last few years, 
transition between S1P treatments has not broadly assessed.  Theoretically, while both 
siponimod and fingo limod demonstrate persistent internalization and enhanced degradation of 
the S1P -receptor, there is clinical utility  in understanding the role of titration, or lack of, when 
converting between the two S1P therapeutic options to ensure patients are not unde rtreated.  
 
Safety  results  from  the Phase  III trial demonstrated  that siponimod  is safe and well tolerated  
• 197 (18%)  patients  on siponimod  and 83 (15%)  on placebo  had at least one serious 
adverse event.  
• Headache, nasopharyngitis, urinary tract infection, and falls were the most frequent 
adverse  events,  being  reported  in more  than 10% of patients  in both treatment  groups 
(siponimod vs placebo)  
• Hypertension  was reported  in 115 patients  (10%)  on siponimod  compared  with 41 (8%)  on 
placebo  
• Four  deaths  occurred  in each treatment  group.  Deaths  in the siponimod  group  were  due to 
metastatic gastrointestinal melanoma within 4 months of commencing siponimod; septic 
shock in a patient with terminal colon  cancer; urosepsis more than 10 weeks after 
discontinuation of siponimod and after two doses of rituximab; and suicide.  
• Cardiac  effects:  1346  (82%)  of 1651  patients  underwent  continuous  mobile  cardiac 
telemetry for up to 6 days.  
• During  double -blind  treatment  initiation, the  maximum  reduction in  mean  heart rate 
• On day 1 was 5.3 bpm in the siponimod  group  (4 h post-dose)  and 1.2 bpm in the 
placebo group (1 h post -dose)  
• On day 7, mean  reductions  were  3.1 bpm and 2.0 bpm,  in siponimod  and placebo 
treated patients, respectively (3 h post -dose)  
• For 68 patients  (6%)  receiving  siponimod  and 17 (3%)  receiving  placebo,  bradycardia, 
decreased heart rate, or sinus bradycardia were reported as adverse events.  
• Two of these  events  on day 7 in the siponimod  group  were  symptomatic,  one leading 
to treatment discontinuation.  
• No cases  of Mobitz  type II or high degree  atrioventricular  block  were  observed  during 
double -blind treatment  
To date,  phase  III studies  have  not examined  the safety  considerations  among  RRMS  or SPMS 
patients  who had undergone  acute  conversion  to siponimod  from  other  DMT  treatment.  As the 
disease  progresses  with a need  to convert  from  one DMT  to another,  assessing  the effects  (safety 
and efficacy) of this acute conversion from existing DMTs becomes important. In order to 
address the benefits and risk needs of a patient and public health relevance across a broad MS  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  35  
Protocol  No. CBAF312AUS02   
 
population representative of clinical practice, it is necessary to understand the implications of 
overlapping immune effec ts, dose titration, washout intervals between therapies, direct 
conversion -related adverse events, conversion between S1P receptor modulators, patient 
tolerability and adherence, which are compulsory to appropriately address the benefit: risk 
needs of a pa tient.  Furthermore, recent market research from the United States reported that 
there is a significant percentage of patients with transitioning RMS that are being treated with 
another class of drugs known as infusion DMTs, specifically, natalizumab (an α4 -integrin 
antagonist, humanized monoclonal antibody) or ocrelizumab (a monoclonal antibody that 
targets  CD20  marker  on B-lymphocytes),  for which  a safety  gap on DMT  conversion  continues 
to persist. Natalizumab, is broadly used in patients with advancing RM S. However, many 
patients need to switch to an alternative therapy due to safety, tolerability, effectiveness, or 
access reasons.  Ocrelizumab has a prolonged immunosuppressive effect primarily resulting 
from a rapid reduction of lymphocyte B -cells, with a median time of 72 weeks (range 27 -175 
weeks)  for this cell counts  to return  to normal  after last infusion.  It is expected  that patients  who 
are currently  treated  with natalizumab  and/or  ocrelizumab  will convert  to siponimod  for reasons 
of safety, tolerability, effectiveness or access. Therefore it is critical to generate data to guide 
discussions between healthcare providers and patients at the time point of conversion, 
immediate and short term safety, and effectiveness after con version.  
 
 
1.2 Purpose  
The purpose of this study is to assess initial safety and tolerability of converting patients from 
approved  oral, injectable  and infusion  RMS  DMTs  to siponimod.  The results  of this study  will 
guide  clinically  relevant  decisions  related  to the transition  from  frequently  used RMS  DMTs  to 
siponimod and provide clinically relevant data on safety and tolerability for healthcare 
providers who are considering converting patients from currently approved RMS DMT to 
siponimod.  
 
 
2 Objectiv es and endpoints  
Table  2-1 Objectives  and related  endpoints  
 
Objective(s)  Endpoint(s)  
Primary  Objective(s)  
• The primary  objective  is to evaluate  overall  safety  and 
tolerability profile of siponimod in advancing RMS 
patients who are converting from currently approved 
oral, injectable or infusion RMS DMT.  Endpoint(s)  for primary  objective(s)  
• Occurrence of any study -drug related 
adverse  events  during  6-month  treatment 
period  
 
 
Secondary  Objective(s)  
• To evaluate treatment satisfaction with siponimod in 
advancing  RMS  patients  using  outcomes  based  on the 
Treatment Satisfaction Questionnaire for Medication 
(TSQM -9). 
• To evaluate  cardiac  safety  during  siponimod  treatment  
initiation  Endpoint(s) for secondary  objective(s)  
• Occurrence  of any adverse events  
• Change  from Baseline  in the TSQM -9 
 
• Change  from Baseline  in heart  rate to 6 
hours after 1st treatment  
 

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  36  
Protocol  No. CBAF312AUS02   
 
 
Objective(s)  Endpoint(s)  
• To evaluate  treatment  persistence  with siponimod  • Occurrence of hospitalizations  
• Patient retention  
 

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  37  
Protocol  No. CBAF312AUS02   
 
3 Study  design  
This is a 6 -month, open -label, multi -center, single arm design, including 300 -400 advancing 
RMS patients, evaluating overall safety and tolerability profile when acutely converting to 
siponimod  from  oral or injectable  or infusion  RMS  DMTs.  This study  consists  of two primary 
parts:  The Screening  Period  and the Core  Treatment  Period,  plus a 30-day follow -up telephone 
call at the end of treatment/study  visit. This study  includes a virtual cohort of patients, i.e., the 
patient  will remain  in their own home  and complete  study  assessments  via an online  technology. 
This virtual cohort of the study is being done in parallel to, but s eparate from, other sites that 
will conduct study visits in the traditional manner, i.e., with all assessments performed at the 
study center.  
• The patient  cohort  will be stratified  by pre-treatment  groups  and may include  injectable, 
oral and infusion DMTs  used in RMS: interferon beta -1a (Avonex®, Rebif®), interferon 
beta-1b (Betaseron®, Extavia®), glatiramer acetate (Copaxone®, generic glatiramer 
acetate), peginterferon beta -1a (Plegridy®), teriflunomide (Aubagio®), fingolimod 
(Gilenya®, including generic forms of fingolimod), dimethyl fumarate (Tecfidera®, 
including generic forms of  dimethyl fumarate, Vumerity® (diroximel fumarate)), 
natalizumab (Tysabri®), and ocrelizumab (Ocrevus®).  
• Patients fulfilling the inclusion criteria, including genotyping, will  undergo immediate 
conversion  (please  see below  for exceptions)  to siponimod,  with “immediate”  defined  as 
cessation of the existing DMT and initiation of siponimod within 24 hours, followed by 
subsequent 5 -day dose titration.  Per inclusion criteria and screening phase testing 
requirements, fingolimod patients will undergo all required screening and/or basel ine 
testing, including genotyping for CYP2C9*1*1.  
• Patients converting specifically from teriflunomide will undergo accelerated 
elimination  prior  to converting  to siponimod  over 11-14 days to allow  for adequate 
drug elimination and minimize drug -drug inte ractions, in line with the Aubagio ® 
USPI.  
• Patients  converting  from  fingolimod  will immediately  convert  to siponimod 
maintenance dose of 2mg, with no dose -titration.  
• Patients  treated  with infusion  DMT  natalizumab  (Tysabri®)  will undergo  at least a 4 
week washout period at the time of consent, prior to converting to dose -titrated 
siponimod.  
• Patients  treated  with infusion  DMT  ocrelizumab  (Ocrevus®)  will undergo  at least 14 
week washout period at the time of consent, prior to converting to dose -titrated 
siponimod.  
• All patients  initiating  siponimod  treatment,  expect  those  converting  from  fingolimod,  will 
be titrated  over 5 days to achieve  a maintenance  dose of 2mg by Day 6 with the following 
schedule of siponimod:  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  38  
Protocol  No. CBAF312AUS02   
 
Figure  3-1 Siponimod  Targe t Daily  Dose  
 
 
 
Patients who have completed the treatment period successfully, will be given the option  to 
terminate from the study or be referred to the MAYZENT patient services hub for post -trial 
continuity of treatment programs, where the benefit risk is acceptable and discussed with the 
patient  and investigator.  Patients  who terminate  prior  to the end of the treatment  period  or who 
withdraw  permanently  due to siponimod  related  AE or SAE  should  follow  up with their primary 
neurologist for continued treatment options as quickly as possible.  
 
Figure  3-2 Exchange  Study  Design  
 
 
  
 
 
 
 
 
 
 
 
 

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  39  
Protocol  No. CBAF312AUS02   
 
 
 
 
 
 
 
4 Rationale  
4.1 Rationale  for study  design  
The clinical development program of siponimod has demonstrated both a favorable efficacy 
and benefit:  risk profile  in RMS  and SPMS  patients.  While  there  is a fair amount  of data on the 
overall  safety  profile  of siponimod,  less data exists  to describe  the safety  and tolerability  profile  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  40  
Protocol  No. CBAF312AUS02   
 
during conversion from existing DMTs to siponimod in a broader population than included in 
the Phase II and Phase  III development  program  and to determine  how health  outcomes  changes 
when patients start treatment with siponimod both short - and long -term.  
This prospective open -label treatment study design supports the need for increased human 
exposure  to a new medicine to further evaluate the safety on the immediate conversion of oral 
injectable, and infusion DMTs to siponimod in patients with advancing RMS.  A treatment 
period of 6 months will allow achieving assessment of potential overlapping immune effects 
from previous DMT at steady state of oral siponimod.  Further, this 6 -month treatment period 
will increase the knowledge of the safety profile of siponimod. The data from the study will 
give HCPs  a better  understanding  of what  the potential  safety  implications  will be with an acute 
conversion of existing DMTs to siponimod.  
This study will include a virtual cohort of patients, i.e., the patient will remain in their own 
home  and complete  study  assessments  via an online  technology.  This virtual  cohort  of the study 
is being done in parallel to, but separate from, other sites that will conduct study visits in the 
traditional manner, i.e., with all assessments performed at the study center. This study design 
element will potentially offer patients b etter access to a clinical trial  
 
 
 
 

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  41  
Protocol  No. CBAF312AUS02   
 
 
 
 
 
 
4.2 Rationale  for dose/regimen  and duration  of treatment  
In the siponimod Phase III (EXPAND) trial, siponimod treatment was initiated with a 5 -day 
dose titrat ion, starting  with 0.25mg  once  daily  on day 1 and 2, followed  by once  daily  doses  of 
0.5mg  on day 3 (two tablets  of 0.25mg),  0.75 mg on day 4 (three  tablets  of 0.25mg)  and 1.25mg 
on day 5 (five tablets of 0.25mg) to reach the maintenance dose of siponimod 2mg starting on 
day 6. It is currently  unknown  whether  this titration  regimen  is needed  among  patients  who are 
converting from existing S1P receptor modulators (e.g., fingo limod) to siponimod.  
Given the recent development of S1P receptor modulators over the last few years in general, 
transition between emerging S1P treatments has not been broadly assessed.  Sustained 
fingolimod induced receptor internalization of S1P receptor s has been demonstrated in a 
number  of separate  studies  (Jo et al., 2005 ); (Oo et al., 2007 ); (Mullershausen  et al., 2009 ). Both 
siponimod and fingolimod are thought to act as a functional S1P1R antagonist, causing 
complete internalization and down‐regulatio n of the S1P1 receptor found on lymphocytes 
(Matloubian  et al., 2004 ); (Chiba  et al., 2006 ); (O’Sullivan  et al., 2016 ). Through  this on-going 
study, there is clinical utility  in substantiating the hypothesis that a direct switch between S1P 
receptor modulators is clinically safe and  effective in sustaining therapeutic coverage. 
Therefore, in this study amendment, we suggest to omit the siponimod titration regimen for 
only those patients converting from fingolimod strata as part of the investigative approach in 
understanding the role of titration, or lack of, when converting between the two S1P receptor 
modulators to ensure patients are not undertreated.  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  42  
Protocol  No. CBAF312AUS02   
 
The EXPAND  trial demonstrated  that 288 (26%)  of 1096  patients  receiving  siponimod  and 173 
(32%) of 545 patients receiving placebo had 3 -month CDP (hazard ratio 0.79, 95% CI 0.65 – 
0.95; relative risk reduction 21%; p=0.013; (Kappos L et al Lancet 2018 ). Headache, 
nasopharyngitis, urinary  tract infection,  and falls were  the most  frequent  adverse  events, being 
reported  in more  than 10% of patients  in both treatment  groups.  There  were  no observed  cases 
of Mobitz type II or higher degree atrioventricular block.  
Because  of the success  of siponimod  in the EXPAND  trial, the data was used as a reference  and 
led to 2mg as the maintenance dose for all the patients in this Phase IIIb study  with a 6 -month 
treatment in the core treatment period for all patients. The data collected from this Phase IIIb 
study will be important to provide a better understanding of the safety profile when acutely 
converting advancing RMS patients to siponimod from standard of car e oral, injectable or 
infusion DMTs.  
 
4.3 Rationale  for choice  of control  drugs  
Not Applicable.  
 
4.4 Purpose  and timing  of interim  analyses/design  adaptations  
Shortly  before  the scheduled  completion  of enrollment  in this study,  an interim  analysis  will be 
performed. Since pre -specification of the parameters relevant for the sample size calculations 
(disease  activity,  enrollment  rate, and dropout  rate) has uncertainty,  it is reasonable  to re-assess 
the pre-study  assumptions  prior  to the completion  of the enrollment  period.  For the purpose  of 
earlier dissemination, an interim analysis on the safety data will be conducted at the time of 
approximately 50 patients completing their Visit 5 (Day 168). This analysis may result in an 
increase  in the total number  of patients  enrolled  in the study.  The maximum  number  of patients 
is specified  in section  5. Additional  interim  analyses  may be conducted  at additional  time points 
based on study enrollment to evaluate continued efficacy and safety data (for example, 50% 
enrollment).  These interim analyses will also allow for an evaluation of the infusion strata.  
 
4.5 Risks  and benefits  
When adhering to the inclusion/exclusion  criteria and PIs guidance on safety conditions, 
providing close clinical monitoring, avoiding prohibited treatments, the risk to patients in this 
trial will be minimized.  
The risk profile of siponimod includes bradyarrhythmia (including conduction effects ) 
occurring post -first dose in patients with heart rate (HR) less than 55 beats per min (bpm) and 
liver transaminase elevation. Risks associated with S1P modulators, but not observed with 
siponimod to date include clinically relevant bronchoconstriction, i ncreased frequency of 
infections,  hypertension  and posterior  reversible  encephalopathy  syndrome.  There  may be yet 
unknown risks to MS patients taking siponimod, which may be serious and unforeseen. There 
is little data from phase III/IIIb clinical trials a sserting safety relevant to acute conversion of 
siponimod from current standard of care treatments.  
With limited treatment options for patients with advancing RRMS and patients progressing to 
or currently  diagnosed  with SPMS,  siponimod  has demonstrated  the potential  to be an effective 
treatment that addresses the current unmet needs for this population.  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  43  
Protocol  No. CBAF312AUS02   
 
Women of child bearing potential and sexually active males must be informed that taking the 
study  treatment may  involve unknown risks to the fetus if pregnancy  were to occ ur during the 
study.  Thus, they must agree to adhere to the contraception requirements outlined in the 
exclusion  criteria  in order  to participate  in the trial. If there  is any question  that the patient  will 
not reliably comply, they should not be entered o r continue in the study.  
 
4.6 Rationale  for public  health  emergency  mitigation  procedures  
During  a Public  Health  emergency  as declared  by Local  or Regional  authorities  i.e. pandemic, 
epidemic or natural disaster, mitigation procedures to ensure participant safety and trial 
integrity  are listed  in relevant  sections.  Notification  of the Public  health  emergency  should  be 
discussed with Novartis prior to implementation of mitigat ion procedures, and 
permitted/approved by Local or Regional Health Authorities and Ethics Committees as 
appropriate.  
 
 
 
5 Population  
This study includes advancing RMS patients.  Because the transition of disease activity from 
RRMS to SPMS is not well -characterized, introducing a functional definition of advancing 
RMS  for purposes  of this study  is aimed  to help identify  patients  who may be demonstrate  onset 
of relatively fixed impa irment indicative or worsening disease activity or progressive disease 
activity.  
The study population will consist of out -patient, male and female patients, ≥18-65 (inclusive) 
years of age, with an EDSS score >2.0-6.5, inclusive, with advancing RMS with or  without 
progressive features.  The diagnosis of MS with initial relapsing remitting disease course is 
defined by the 2010 revised McDonald criteria (Polman et al 201 1). EDSS >2 defines the 
beginning of relatively fixed impairment.  Worsening denotes an increase in neurological 
dysfunction and/or disability, with or without evidence of relapses or disease activity on MRI 
(Lublin et al 2013).  Progression denot es the continuous or steady worsening of neurological 
impairment over at least 6 months (Rovaris et al 2006 ) not explained by incomplete recovery 
from relapses (Lublin et al 2013).  
Patients  who have  been  previously  treated  with other  MS therapies,  such as interferon  beta-1a, 
interferon beta -1b, glatiramer acetate, fingoli mod, fumarates (dimethyl fumarate, diroximel 
fumarate), teriflunomide, natalizumab or ocrelizumab for at least 3 months at the time of 
consent may participate. Approximately 300 -400 patients will be randomized from up to 80 
study sites in the USA.  The stud y plans to screen approximately 570 patients.  
At the time of enrollment, patients are eligible if they are identified as clinically appropriate 
advancing RMS patients and eligible to receive siponimod, as well as meeting all other 
eligibility criteria . 
 
5.1 Inclusion  criteria  
Patients  eligible  for inclusion  in this study  must  meet  all of the following  criteria:  
1. Signed  informed  consent  must  be obtained  prior  to participation  in the study.  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  44  
Protocol  No. CBAF312AUS02   
 
2. Male  or female  aged 18 to  65 years  (inclusive)  at screening  
3. Patients  with advancing  RMS  as defined  by the principal  investigator  
4. Prior  history  of relapsing  MS (RMS),  with or without  progressive  features,  according  to 
the 2010 Revised McDonald or Lublin criteria (Lublin et al 2013 ) 
5. Disability  status at screening with an EDSS  score of  >2.0 to 6.5 (inclusive)  
6. Having been continuously treated with beta -interferons, glatiramer acetate, fingolimod, 
fumarates  (dimethyl  fumarate,  diroximel  fumarate),  or teriflunomide  for at least 3 months 
at the time of consent OR having had last natalizumab dose at least 4 weeks be fore 
screening OR last ocrelizumab dose 14 weeks prior to screening.  
 
5.2 Exclusion  criteria  
Patients m eeting any of the following criteria are not eligible for inclusion in this study.  No 
additional exclusions may be applied by the investigator in order to ensure that the study 
population will be representative of all eligible patients:  
1. Patients  with an active  chronic  disease  (or stable  but treated  with immune  therapy)  of the 
immune system other than MS (e.g., rheumatoid arthritis, scleroderma, Sjogren’s 
syndrome, Crohn’s disease, ulcerative colitis, etc.) or with a known immunodeficiency 
syndrome (AIDS,  hereditary immune deficiency, drug -induced immune deficiency).  
2. Pregnant  or nursing  (lactating)  women,  where  pregnancy  is defined  as the state of a female 
after conception and until the termination of gestation, confirmed by a positive hCG 
laboratory test.  
3. Women of child -bearing potential, defined as all women physiologically capable of 
becoming  pregnant,  unless  they are using  highly  effective  meth ods of contraception  while 
taking study treatment and for 30 days (30 days = 5 times the terminal half -life of 
siponimod) after stopping study treatment. Highly effective contraception methods 
include:  
• Total abstinence (when this is in line with the pref erred and usual lifestyle of the 
patient.  Periodic  abstinence  (e.g.,  calendar,  ovulation,  symptothermal,  post-ovulation 
methods) and withdrawal are not acceptable methods of contraception  
• Female sterili zation (have had surgical bilateral oophorectomy with or without 
hysterectomy), total hysterectomy, or tubal ligation at least six weeks before taking 
study  treatment.  In case of oophorectomy  alone,  only when  the reproductive  status  of 
the woman has been c onfirmed by follow up hormone level assessment  
• Male  sterilization  (at least 6 months  prior  to screening).  For female  patients  on the 
study, the vasectomized male partner should be the sole partner for that patient  
• Use of oral, (estrogen  and progesterone),  injected  or implanted  hormonal  methods  of 
contraception or placement of an intrauterine device (IUD) or intrauterine system 
(IUS), or other forms of hormonal contraception that have comparable efficacy 
(failure rate <1%), for example hormone  vaginal ring or transdermal hormone 
contraception.  
• In case of use of oral contraception  women  should  have  been  stable  on the same  pill 
for a minimum of 3 months before taking study treatment.  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  45  
Protocol  No. CBAF312AUS02   
 
• Women are considered post -menopausal and not of child bearing potential if they 
have  had 12 months  of natural  (spontaneous)  amenorrhea  with an appropriate  clinical 
profile (e.g. age appropriate history of vasomotor symptoms) or have had surgical 
bilateral oophorectomy (with or without hysterectomy), total hysterectomy or tubal 
ligation at least six weeks ago. In the case of oophorectomy alone, only when the 
reproductive status of the woman has been confirmed by follow up hormone level 
assessment is she cons idered not of child bearing potential.  
4. Sexually active males unwilling to use a condom during intercourse while taking study 
treatment  and for 30 days (30=  5 times  the terminal  half-life of siponimod)  after stopping 
study  treatment.  A condom  is required  for all sexually  active  male  participants  to prevent 
them  from  fathering  a child  AND  to prevent  delivery  of study  treatment  via seminal  fluid 
to their partner. In addition, male participants must not donate sperm for the time period 
specified above.  
If local  regulations  deviate  from  the contraception  methods  listed  above  to prevent 
pregnancy, local regulations apply and will be described i n the ICF.  
 
5. History  of malignancy  of any organ  system  (other  than localized  basal  cell carcinoma  of 
the skin), treated or untreated, within the past 5 years, regardless of whether there is 
evidence of local recurrence or metastases.  
6. Diabetes mellitus , unless well controlled and without known organ complications 
including  but not limited  to heart  disease  reduced  renal  function,  significant  retinal 
pathology or neuropathy.  
7. Diagnosis  of macular  edema  1 year prior  to screening.  
8. Patients  with active  systemic  bacterial,  viral,  or fungal  infections  or known  to have  AIDS 
or have positive HIV antibody.  
9. Positive  results  of screening  period  testing  for serological  markers  for hepatitis  A, B, C 
and E, indicating acute or chronic infection:  
• anti-HAV  IgM 
• HBs Ag and/or  anti-HBc IgM 
• anti-HEV  IgM (if positive  IgG and/or IgM,  perform  HEV -RNA  PCR  and if negative, 
patient can be included).  
Note:  If the trea ting physician suspects false positive hepatitis serology  results, such as an 
antibody pattern indicating acute hepatitis infection but no corresponding elevated liver 
enzymes and no signs or symptoms of liver disease, a HEV -RNA PCR will be performed 
and will be the deciding  factor  to determine  whether  the patient  has hepatitis  A, B, C, or E. 
If negative, the treating physician may  document (in source data and in a eCRF comment) 
that the serology results are considered false positive and consider including the patient.  
10. Negative  for varicella -zoster  virus  IgG antibodies  at Screening  unless  there  is other 
evidence of immunity to VZ V based on the CDC criteria 
(https://www.cdc.gov/chickenpox/hcp/imm unity .html; see Appendix 1 ) 
11. Have  received  any live or live-attenuated  vaccines  (including  for varicella -zoster  virus  or 
measles) within 2 months of screeni ng. 
12. Have been treated with any  of the medications listed below:  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  46  
Protocol  No. CBAF312AUS02   
 
• Intravenous  immunoglobulin  within  2 months  prior  to screening  
• Immunosuppressive/chemotherapeutic  medications  (e.g.,  azathioprine,  methotrexate) 
within 6 months prior to screening  
• Cyclophosphamide  within  2 years  prior  to screening  
• More  than 24 months  prior  treatment  exposure  to natalizumab  
• Rituximab,  ofatumumab,  ublituximab  or cladribine  within  2 years  prior  to 
randomization  
• Alemtuzumab at any  time 
• Any mitoxantrone during previous 2 years prior to randomization or evidence of 
cardiotoxicity  following  mitoxantrone  or a cumulative  life-time dose of more  than 60 
mg/m2  
• If patients  treated  with teriflunomide  cannot or will not undergo  the accelerated 
elimination process Appendix 6 . 
• Stem  cell transplantation  
• Lymphoid  irradiation,  bone  marrow  transplantation  or other  immunosuppressive 
treatments with effects potentially lasting over 6 months, at any time.  
13. Patients with any  medically  unstable condition as determine by  the investigator.  
14. Any of the following  conditions  or treatments  that may affect  cardiovascular  function 
within the last 6 months:  
• Heart  rate < 55 bpm at screening  
• Cardiac  conduction  disorders  such as incomplete  left bundle  branch  block  or second 
degree AV block Mobitz type I (Mobitz I) (either history or observed at screening)  
• Minor  ECG  findings  at screening  PR interval:  >200  msec;  QRS  duration  ≥120 msec; 
QTcF >430 msec (males); QTcF >450 msec (females)  
• History of or current significant car diac disease including cardiac failure (NYHA 
functional  class  II-IV), myocarditis,  cardiomyopathy,  angina  pectoris  or myocardial 
infarction (within 6 months), unstable angina (within 6 months), stroke (within 6 
months), TIA (within 6 months), decompensated heart failure requiring 
hospitalization (within 6 months) or uncontrolled arterial hypertension  
• History  of (within  the 6 months)  or current  cardiac  disease  such as heart  failure 
NYHA class I, history of myocardial infarction prior to enrollment.  
• Patients  receiving  treatment  with beta-blockers  for cardiac  disease/comorbidities  
• Any other  condition  which,  in the opini on of the investigator,  has a potential  for AV 
conduction suppression and/or other risk factors that may require expanded cardiac 
monitoring  
• Patients  diagnosed  with right  bundle  branch  block,  either  at the Screening  visit for 
entry of the study or during the conduct of the study  
15. Any of the following pulmonary  conditions:  
• History  of or active  severe  respiratory  disease,  including  COPD,  or pulmonary 
fibrosis,  
• Tuberculosis,  except  for history  of successfully  treated  tuberculosis  or a history  of 
prophylactic treatment after positive PPD skin reaction  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  47  
Protocol  No. CBAF312AUS02   
 
• Patient  with severe  asthma  or asthma  requiring  regular  treatment  with oral steroids  
16. Patients with any  of the following hepatic conditions prior to screening:  
• history  of alcohol abuse, chronic liver or biliary  disease  
• total or conjugated  bilirubin  greater  than 1.5 times  ULN  range,  unless  in the context 
of Gilbert’s syndrome  
• alkaline  phosphatase  (AP) greater  than 1.5 times  the ULN  range  
• AST  (SCOT),  ALT  (SGPT)  or Gamma -glutamyl -transferase  (GGT)  greater  than 3 
times the ULN range within the last 6 months  
17. Any of the following abnormal laboratory  values prior to screening:  
• Serum  creatinine  > 1.7 mg/dL  (150 umol/L)  
• White  blood  cells (WBC)  count  <3,500/mm3  (<3.5  x 10(9)/L),  while  on oral DMT’s 
at screening, except fingolimod  
• Lymphocyte  count  <500/mm3  (<0.5  x 10(9)/L)  while  on all DMT’s  at screening 
except fingolimod  
• Serum  potassium  > ULN  
• Or other  clinically  significant  laboratory  assessment  (i.e. hypomagnesemia  or 
hypokalemia)  
• For patients  previously  exposed  to natalizumab,  anti-JCV antibody  positive  and index  
> 1.5 
18. Patients  with the following  neurological/psychiatric  disorders  prior  to screening:  
• History of substance abuse (drug or alcohol) or any other factor (i.e. serious 
psychiatric  condition)  that may interfere  with the patient’s  ability  to cooperate  and 
comply with the study protocol  
• Progressive  neurological  disorder,  other  than MS, which  may affect  participation  in 
the study or require the use of medications not allowed by the protocol  
19. Use of other  investigational  drugs  at the time of enrollmen t or within  prior  30 days;  or five 
eliminati on half -lives, or until the expected pharmacodynamics effect has returned to 
baseline, whichever is longer.  
20. History  of hypersensitivity  to the study  drug or to drugs of  similar  chemical classes.  
21. Homozygosity  for CYP2C9*3/*3  or heterozygous  for CYP2 C9*2/*3  or CYP2C9*1/*3 
(to be tested at screening) or refusal to test for CYP2C9 variants.  
22. Concomitant  use of MAYZENT  and drugs  that cause  moderate  CYP2C9  and moderate  or 
strong CYP3A4 inhibition ( Appendix 4 ). 
23.  Concomitant  use of MAYZENT  and drugs  that cause  moderate  CYP2C9  and strong  
CYP3A4 induction ( Appendix 4 ). 
24. Use of cannabinoid  or cannabidiol  products  30 days  prior  to screening.  
25. Any other disease or condition, which could interfere with participation in the study 
according  to the study  protocol,  or with the ability  of the patients  to cooperate  and comply 
with the study procedures.  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  48  
Protocol  No. CBAF312AUS02   
 
Note  1: If a patient  fails on one or more  laboratory  (or other)  assessment  criteria,  as part of the 
screening process, the assessment (s) may be repeated at the discretion of the investigator and 
the patient may be included if criteria are then met, provided the assessments are completed 
within the screening period.  
Note  2: In certain  cases  rescreeni ng of patients  that were  previously  determined  ineligible  may 
be permitted.  When a patient is re -screened, a new patient identification number will be 
assigned and all screening assessments must be repeated. Each patient may be rescreened no 
more than 1 ti me. 
No additional exclusions may be applied by the investigator, in order to ensure that the study 
population will be representative of all eligible patients.  
 
 
6 Treatment  
6.1 Study  treatment  
6.1.1  Investigational  and control  drugs  
Chemical  Name:  Siponimod  
Other  Names:  BAF312,  Mayzent  ® 
Classification:  Oral sphingosine  1-phosphate  receptor  modulator  
The investigational  drug siponimod  will be provided  as film coated  tablets.  Please refer  to the 
pharmacy manual provided for specific instructions.  
The study  medication  will be administered  orally,  once  daily,  with or without food.  
Should titrated patient miss one day of titration or more, the patient will need to restart the 
titration  with Day 1 dosing  (0.25mg),  including  Day 1 cardiac  assessments  (pre-dose ECG  and 
6-hour post dose heart rate). It is strongly recommended, during the titration phase, that a 
member  of the study  staff contact  the patient,  once  daily  via phone,  to remind  them  to take their 
study medication as required. This is because restarting the titration will require the patient to 
come in for an unscheduled visit to do a pre -dose ECG assessment and 6 hour post -dose heart 
rate (holter telemetry monitoring).  
Furthermore, if mai ntenance treatment (2mg) is interrupted for 4 or more consecutive daily 
doses, treatment must be re -initiated with the 5 -day titration, including pre -dose ECG and 6 - 
hour post -dose heart rate (holter telemetry monitoring) at an unscheduled visit.  Treatment  
interruptions for up to 3 missed consecutive daily doses does not require re -titration, and 
treatment should be continued at the maintenance dose level.  
If the patient has missed greater than 30 consecutive days of treatment, using his/her best 
medical ju dgement, the PI should consider terminating the patient from the study.  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  49  
Protocol  No. CBAF312AUS02   
 
Table  6-1 Core  Treatment  Period  
 
Treatment  
arm # of 
patient’s  Type  of study  
drug  Compound  Min. 
Dose  Max.  
Dose  Frequency  Formulation  Admin  
Route  Generic  
acceptabl  
e 
Arm 1 300 - 400 Investigational  Siponimod  0.25 
mg 2 mg Daily  Tablet  Oral No 
 
6.1.2  Additional  study  treatments  
No other treatment  beyond investigational  drug and  control drug  are included  in this trial. 
 
6.1.3  Treatment arms/group  
All patients,  except  those  converting  from  fingolimod,  will be assigned  at visit 1 (Day  1) to the 
following  single -treatment arm:  Siponimod 0.25mg  (initial  dose).  Following  initial  dose,  the 
titration schedule will be as follows: Day 2 (0.25mg), Day 3 (0.5mg), Day 4 (0.75mg), Day 5 
(1.25mg) and Day 6 and for the rest of the study (2.0mg) as shown in Table 6 -3. 
 
6.1.4  Treatment duration  
The planned duration of the core treatment period is 6 months. Patients  may discontinue from 
treatment earlier due to unacceptable toxicity, disease progression and/or at the discretion of 
the investigator  or Novartis.  For patients  who in the opinion  of the investigator  are still deriving 
clinical benefit from siponimod, every effort will be made to continue study treatment.  
 
6.2 Other  treatment(s)  
6.2.1  Concomitant therapy  
The investigator should instruct the patient to notify the study site about any new medications 
he/she  takes  after the patient  enrolls  into the study.  All medications,  procedures  and significant 
non-drug therapies (including physical therapy and blood transfusions) administered after the 
patient  enrolls  into the study  must  be recorded  on the appropriate  Electronic  Case  Report  Forms 
(eCRF). Each concomitant drug must be assessed against  all exclusion criteria/prohibited 
medications. If in doubt, the investigator should contact the Novartis medical monitor before 
randomizing a patient or allowing a new medication to be started. If the patient is already 
enrolled,  contact  Novartis  to deter mine  if the patient  should  continue  participation  in the study.  
 
6.2.1.1  Permitted  concomitant  therapy  requiring  caution  and/or  action  
The investigator should instruct the patient to notify  the study  site about any new medications 
he/she takes after the patient enrolls into the study.  
Since  heart  rate is an important  variable  affecting  the QT interval,  starting  medications  affecting 
QT-prolongation (e.g. beta -blockers), during siponimod treatment initi ation (e.g., the first 10 
days)  should  be avoided whenever  possible.  Beta-blocker  treatment for non -cardiac  treatment 
purposes  can be introduced  in patients  who are receiving  a maintenance  dose of study  treatment.  
Experience with siponimod is limited in patients receiving concurrent therapy with heart -rate 
lowering calcium channel blockers (such as verapamil or diltiazem), or other medications that 
may decrease heart rate (e.g., ivabradine or digoxin).  Concomitant u se of these medications 
during  siponimod  initiation  may be associated  with severe  bradycardia  and heart  block;  because  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  50  
Protocol  No. CBAF312AUS02   
 
of these potential effects on heart rate, siponimod should not be initiated in patients who are 
concurrently treated with these medications . 
 
6.2.2  Prohibited medication  
Use of the medications displayed in Table 6 -2 is NOT allowed throughout the study duration 
due to increased risk of immunosuppressi on with siponimod (CYP2C9 is the major 
metabolizing enzyme for siponimod).  
If one of these prohibited medications is taken during the treatment period, the prohibited 
medication  must  be stopped  immediately.  Additional action may  be required per  the direction 
of the Novartis.  
 
Table  6-2 Prohibited  medication  
Medication  Prohibition  
period  
Immunosuppressive/chemotherapeutic 
medications or procedures, including   
 
Action  taken  
 
Discontinue  or Interrupt  study  treatment, 
increase vigilance regarding infections.  
cyclosporine,  azathioprine,  
methotrexate, cyclophosphamide, 
mitoxantrone,  lymphoid  irradiation  and 
hematopoietic stem cell  
transplantation  duration  of 
study  NOTE: Restarting study treatment in 
patients exposed to these medications 
must  first be discussed  with the Novartis 
Medical Advisor.  
 
Monoclonal antibodies targeting the 
immune  system,  including,  rituximab, 
ofatumumab, and alemtuzumab, 
ublitixumab  duration  of 
study  Discontinue  study  treatment,  increase 
vigilance regarding infections.  
 
Any concomitant medication which 
inhibits cardiac conduction, e.g. 
verapamil -type and diltiazem -type 
calcium  channel  blockers  or cardiac 
glycosides  
 
Potent  inducers  of CYP2C9  (Appendix 
4) 
 
6.3 Treating  the patient  
6.3.1  Patient  numbering   
duration  of 
study  
 
 
 
duration  of 
study   
Discontinue  study  treatment  
 
 
 
Discontinue  study  treatment  
Each  patient  is identified  in the study  by a Patient Number  (Patient  No.),  that is assigned  when 
the patient consents and enters the screening period in the study; the number is retained as the 
primary  identifier  for the patient  throughout  his/her  entire  participation  in the trial. The Patient 
Number consists of the Center Number, (as assigned by Novartis to the study site), with a 
sequential patient number suffixed to the Center Number. This provides each patient with a 
unique  number  across  the entire  database.  Once  assigned  to a patien t, the Patient  Number  will 
not be reused.  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  51  
Protocol  No. CBAF312AUS02   
 
Upon  signing  the informed  consent  form,  the patient  is assigned  the next sequential  number  by 
the investigator.  The investigator  or his/her  staff will contact  the IRT and provide  the assigned 
patient study identification number along with the requested identifying information of the 
patient to register them into the IRT.  The site will enter this number on the electronic case 
report form (eCRF) in the electronic data capture system (EDC ). 
If the patient  fails to be assigned  to treatment  for any reason,  the IRT must  be notified  within  2 
days that the patient was not assigned to treatment.  The reason for not being assigned to 
treatment will be entered on the Screening Phase Disposition eCR F. 
 
6.3.2  Treatment assignment  
Patients  will receive  siponimod  on Day 1 (Visit  1). The initial  dose given  to all patients,  except 
fingolimod strata, will be 0.25 mg.  The initial siponimod dose given to patients converting 
from fingolimod will be given 2 mg. Fingolimod patients will receive an additional telephone 
call, from site staff, at the end of Day 1 as part of additional safety measures.  
 
6.4 Treatment  blinding  
This is an open  label  study.  
 
6.5 Dose  escalation  and dose  modification  
Siponimod dose adjustments are not permitted.  Any dose interruptions due to adverse events 
should be documented in the eCRF and dose administration record.  
 
6.6 Additional  treatment  guidance  
6.6.1  Treatment compliance  
Compliance will be assessed by  the investigator and/or study  personnel at each visit using pill 
counts  and information  provided  by the patient/caregiver.  This information  should  be captured 
in the source  document  at each visit.  Patient  compliance  should  be at 100%  during  the titration 
period.  During the maintenance treatment period, patient compliance should be at 80% 
minimum. The investigator and/or study personnel will counsel the patient if compliance is 
below 80%.  Study drug accountability will also be determined by the site monitor while 
performing routine site visits and at the completion of the study.  
Duration of the study titration and maintenance study drug exposure will be calculated based 
upon the start and stop dates recorded in the Dosage Administration Record eCRF.  
 
6.6.2  Emergency  breaking of assigned treatment code  
Not applicable - Open  label  
 
6.7 Preparation  and dispensation  
Each  study  site will be supplied  with siponimod  as described  in the pharmacy  manual. 
Siponimod will be administered to the patient orally.  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  54  
Protocol  No. CBAF312AUS02   
 
Informed  consent  must  be obtained  before  conducting  any study -specific  procedures  (e.g. all of 
the procedures described in the protocol). The process of obtaining informed consent must be 
documented in the patient source documents.  
Novartis  will provide  to investigators  in a separate  document  a proposed  informed  consent  form 
that complies with th e ICH GCP guidelines and regulatory requirements and is considered 
appropriate for this study. Any changes to the proposed consent form suggested by the 
investigator must be agreed by Novartis before submission to the IRB/IEC.  
Information about common side  effects already known about the investigational drug can be 
found in the Investigator's Brochure (IB) (and/or CDS for marketed drugs) . This information 
will be included  in the patient  informed  consent  and should  be discussed  with the patient  during 
the st udy as needed. Any new information regarding the safety profile of the investigational 
drug that is identified between IB updates will be communicated as appropriate, for example, 
via an investigator notification or an aggregate safety finding. New informa tion might require 
an update to the informed consent and then must be discussed with the patient.  
Women  of child  bearing  potential  must  be informed  that taking  the study  treatment  may involve 
unknown risks to the fetus if pregnancy were to occur during the study and agree that in order 
to participate in the study they must adhere to the contraception requirements.  
Male patients must be informed  that if a female  partner  becomes  pregnant  while  he is enrolled 
in the study,  contact  with the female  partner  will be attempted  to request  her consent  to collect 
pregnancy outcome information.  
A copy  of the approved  version  of all consent  forms  must  be provided  to Novartis  after IRB/IEC 
approval.  
Patients might be asked to complete an optional questionnaire to provide feedback on their 
clinical  trial experience.  This information  is provided  in the consent  form  and explains  that the 
data will be kept anonymized,  and will be used to underst and where  improvement  can be made 
in the clinical trial process. This questionnaire would not ask about the patient’s disease or 
symptoms and therefore will not be considered to be trial data.  
As per Section  4.6, during a Public Health emergency as declared by Local or Regional 
authorities  i.e. pandemic,  epidemic  or natural  disaster,  that may challenge  the ability  to obtain 
a standard written informed consent due to limits that prevent an on -site visit, Investigator 
may conduct the informed consent discussion remotely (e.g. telephone, videoconference) if 
allowable by a local Health Authority.  
Guidance issued by local r egulatory bodies on this aspect prevail and must be implemented 
and appropriately  documented  (e.g. the presence  of an impartial  witness,  sign/dating  separate 
ICFs by trial participant and person obtaining informed consent, etc.).  
 
8 Visit  schedule  and assessments  
Assessment  schedule Table 8 -1 lists all of the assessments and when they are performed. All 
data obtained  from  these  assessments  must  be supported  in the patient’s  source  documentation.  
 Disease  Modifying Therapy  Washout  Regimen  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  55  
Protocol  No. CBAF312AUS02   
 
Pre-treatment  strata  drug name  Washout  Interval  Guidance  
Interferon -beta/glatiramer  acetate  None; immediate  conversion to dose -titrated 
siponimod  
Fumarates  (dimethyl  fumarate,  diroximel 
fumarate)  None; immediate  conversion to dose -titrated 
siponimod  
Teriflunomide  11-14 day acceler ated elimination protocol 
(Appendix 6) prior to starting dose -titrated 
siponimod  
Fingolimod  None;  immediate  conversion  to siponimod 
maintenance dose 2mg  
Natalizumab  Last natalizumab dose at least 4 weeks prior 
to screening  
Ocrelizumab  Last ocrelizumab  dose at least 14 weeks  prior 
to screening  
 
 
No washout is required for patients converting from interferon -beta or fumarates (dimethyl 
fumarate, diroximel fumarate) prior to starting dose -titrated siponimod.  
An accelerated elimination ( Appendix 6 ) interval will be required for patients taking 
teriflunomide before the patient can start treatment with siponimod.  At least 2 weeks with 
successful accelerated teriflunomide elimination procedure as described in t he product label 
should be conducted for these patients.  If accelerated elimination is not possible, the patient 
cannot participate in the study.  
No washout period or titration regimen is required for patients converting from fingolimod to 
siponimod and CY P2C9 *1/*1, *1/*2, or *2/*2 genotyped patients will start directly on 2mg 
maintenance dose upon entering the treatment period.  
At least a 4 week interval will be required for patients converting from natalizumab. 
At least a 14 week  interval  will be require d for patients  converting  from ocrelizumab.  
• On Visit  1 (Day  1, baseline),  patients  who met eligibility  criteria  will have  pre-dose body 
temperature, res piration rate, blood pressure, ECG and heart rate assessed prior to initial 
dose of siponimod.  6 hours after the initial dose of siponimod, heart rate will be 
measured  again.  The study  site personnel  will instruct  the patient  on how to obtain  the 6- 
hour p ost dose heart rate.  Pre-dose ECG may  be obtained via vendor -supplied ECG vest 
and pre -dose HR may be obtained either manually  (see below for guidance) or via ECG. 
Post-dose HR may be obtained via vendor -supplied HR monitoring device.  
• During  all other  study  visits,  outside  of Day 1 (screening,  V2, V3, V4 and  V5) a qualified 
study personnel, as determined by the PI, will assess the patient’s heart rate.  
• Patients  will then follow  the normal  visit schedule  in the treatment  period  and should 
complete all of the relevant assessments as indicated in Table 8 -1. 

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  56  
Protocol  No. CBAF312AUS02   
 
Patients  should  have  all visits/assessments  as outlined  in the Assessment  schedule  Table  8-1 or 
as close  to the designated  day/time  as possible  with an allowed  visit window  of +3 days for visit 
1 (BSL), an a llowed visit window of ± 5 days for visits 2, 3, 4, 5 and an allowed ±7 days for 
the 30 -day telephone follow -up. Missed or rescheduled visits should not lead to automatic 
discontinuation.  
Patients who prematurely discontinue the study for any reason should  be scheduled for a visit 
as soon as possible, at which time all of the assessments listed for the final visit will be 
performed. At this final visit, all dispensed investigational product should be reconciled, and 
the adverse event and concomitant medicat ions recorded on the eCRF.  
 
End of Treatment/Study  (EOT/S)  Visit  Schedule  
For patients who complete the core treatment period of the study, the end of treatment/study 
visit should be conducted.  No study drug should be taken on the day of EOT/S.  
For patient s who discontinue study medication prematurely in the core treatment period, the 
end of treatment/study visit should be conducted when they stop taking study medication.  
A follow -up telephone  call, 30 days after the end of treatment/study  visit,  will be conducted  for 
all patients who randomize.  
As per Section  4.6, during a Public Health emergency as declared by Local or Regional 
authorities i.e. pandemic, epidemi c or natural disaster that limits or prevents on -site study 
visits, alternative methods of providing continuing care may be implemented by the 
investigator as the situation dictates. If allowable by a local Health Authority and depending 
on operational  capabilities,  phone  calls,  virtual  contacts  (e.g. tele consult)  or visits  by site staff/ 
home  nursing  staff to the participant´s  home,  can replace  on-site study  visits,  for the duration 
of the disruption until it is safe for the participant to visit the site again.  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  61  
Protocol  No. CBAF312AUS02   
 
 
 

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  62  
Protocol  No. CBAF312AUS02   
 
8.1 Screening  
Screening Period:  The duration of the screening period w ill be approximately 28 days from 
time of signed informed consent (ICF) to determine patients’ eligibility  for the study  based on 
the inclusion/exclusion criteria and assessments listed below.  Patients deemed eligible will 
enter the core treatment period a t the Baseline visit. While all screening assessments for the 
patients enrolled at the traditional sites are expected to be conducted on -site, the option for 
home  health  nursing  may be utilized  to replace  on-site study  visits  for the remainder  of the trial. 
The screening  period  will include  the following  assessments  (approximately  -28 Days):  
• Obtain:  signed  ICF; patient  history;  demography;  relevant  medical  history  and current 
medical history; prior and concomitant medications  
• Assess: EDSS, physical  exam; if the patient is having a MS relapse; neurological exam; 
height;  weight;  body  temperature;  respiration  rate; blood  pressure;  heart  rate (taken  at the 
clinic by a qualified study staff as determined by the PI); lab assessments (blood 
chemistry; pregnancy;  CYP2C9 haplotype); ECG (12 -lead); CD19+ 
titer only for patients converting from ocrelizumab.  
• Heart rate may be captured via ECG or manual reading.  Should the heart rate need to be 
manually measured by a qualified study staff as determined by the PI, sitting heart rate 
should be taken three times after the patient has been sitting for five minutes with their 
back supported and both feet placed on the floor.  Repeated sitting measurements should 
be made  at 1-2 minute  intervals.  The average  of the 3 heart  rates  assessed  will be noted  in 
the eCRF.  
• Patients fulfilling the eligibility  criteria may  be en rolled into the study  
 
Rescreening : Rescreening may be allowed under certain conditions.  Each patient may be 
rescreened  no more  than once.  Request  from  the investigator/site  staff to rescreen  patients  will 
be handled  on a case-by-case basis  with Clinical Trial  Lead  approval  required  before  proceeding 
with the rescreening.  Rescreening cannot be done if a patient was previously enrolled in the 
study.  
If a patient rescreens for the study, the patient must sign a new informed consent (ICF) and be 
issued  a new patient  number  prior  to any screening  assessments  being  conducted  under  the new 
patient number. The date of the new informed consent signature must be entered on the 
Informed Consent eCRF to correspond to the new patient number.  
 
8.1.1  Information  to be collected  on screening  failures  
All patients who have signed informed consent but not entered into the next period will have 
the study completion page for the screening period, demographics, inclusion/exclusion, and 
serious  adverse  event  (SAE)  data collected.  Adverse  events  that are not SAEs  will be followed 
by the investigator and collecte d only in the source data.  For all patients who have signed 
informed consent and are entered into the treatment period of the study will have all adverse 
events occurring after informed consent is signed recorded on the Adverse Event eCRF.  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  63  
Protocol  No. CBAF312AUS02   
8.2 Patient  demographics/other  baseline  characteristics  
Patient demographic and baselin e characteristic data are to be collected on all patients include 
age, sex,  race, and ethnicity. Relevant medical history/current medical condition data includes 
data until the start of study.  Physical  examination,  vital signs,  laboratory  sampling,  pregnan cy 
testing, ECG, weight,  and previous  MS treatment, EDSS,  will be recorded on 
eCRF.  Where possible, diagnoses and not symptoms, will be recorded.  MS medications will 
be recorded on eCRFs designed to facilitate separation from non -MS medicatio ns. The last 
RMS DMT administered right before converting to siponimod will be recorded.  Likewise, 
detailed MS history and other relevant medical history will be recorded on eCRFs separately 
from relevant non MS medical. In order to collect accurate inform ation about study drug 
exposure, records of study medication dispensed and returned, doses administered and visit 
dates should be maintained for each patient and transcribed into the Dosage Administration 
record eCRF.  Compliance will be assessed by  the inv estigator and/or study personnel at each 
visit.  The study  monitor will perform and document drug accountability  during site visits and 
at the end of the study . 
 
 
8.3 Efficacy/Pharmacodynamics  
Pharmacodynamics assessments  are not measured  in this study.  
 
 
  
 
  
 
  
  
 
 
 
8.4 Safety/Tolerability  
Safety assessments and tolerability will be assessed by collecting adverse events (AEs) and 
serious adverse events (SAEs) at all visits during the treatment period.  
For details  on AE collection  and reporting,  refer  to AE section.  
As per Section  4.6, during a Public Health emergency as declared by Local or Regional 
authorities i.e. pandemic, epidemic or natural disaster, that limits or prevents on -site study 
visits,  regular phone or virtual calls can occur for safety monitoring and discussion of the 
participant´s health status until it is safe for the participant to visit the site again.  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  64  
Protocol  No. CBAF312AUS02   
Table  8-3 Physical  Assessments  
Assessment  Specification  
 
Physical  examination  will be performed  by a qualified  licensed  RN, PA or NP (MD/PI  must  be 
present) or neurologist (MD) at site clinic (traditional sites) or by a licensed RN for sites 
participating virtually (virtual sites) at the visits indicated in the treatment period assessment  
Physical 
examination  
 
 
 
 
 
 
Neurological 
Exam  
 
 
 
Height  and 
Weight  
 
 
 
Vital Signs  schedule and will include an assessment of skin, head, neck, lymph nodes, heart, lungs, 
abdomen, back, neurological function and comments on general appearance.  All significant 
findings that are present prior to signing informed consent must be reported on  the relevant 
medical  history/current  medical  conditions  eCRF.  Significant  findings  made  after singing  the 
informed  consent  and being  randomized  meets  the definition  of an AE and must  be recorded 
on the adverse events eCRF.  
A concise neurological examination will be performed by a qualified licensed RN, PA or NP 
(MD/PI must be present) or neurologist (MD) at site clinic (traditional sites) or by a licensed 
RN for sites participating virt ually (virtual  sites)  at the visits  indicated  in the treatment period 
assessment schedule and will include clinical history combined with a concise evaluation of 
the mental  status,  cranial  nerves,  coordination,  sensory,  motor  and/or  gait. In the event  of a 
suspected  relapse  or exacerbation,  a comprehensive  neurological  exam  may be needed,  at 
the discretion  of the physician,  to thoroughly  evaluate  cranial  nerve  II-XII, reflexes,  strength, 
sensory and motor function and gait  
Height, in centimeters (cm) if p ossible, will be measured at screening visit and end of 
treatment/study  visit. Body  weight,  to the nearest  0.1 kilogram  (kg), in indoor  clothing,  but 
without shoes, will be measured at every visit except Visits 2.  
Vital signs  will be assessed  at every  visit. This will include  blood  pressure  and heart  rate 
measurements.  BP will be medium sized cuff and the noon -dominant arm in the sitting 
position  after 5 minutes  of rest. Every  effort  should  be made  to use the same  arm for the 
patient for all vital signs assessments and where possible, the same person doing the 
assessment.  
Clinically  notable  vital signs  are defined  in Appendix  1. 
 
 
 
8.4.1  Laboratory  evaluations  
 
Table  8-4 Laboratory  Assessments  
 
Test Category  Test Name  
 
Red blood  cells,  total White  blood  cells,  Differential  White  blood  cells (Basophils,  
Hematology  
 
 
 
Chemistry  Eosinophils,  Lymphocytes,  Monocytes,  Neutrophils,  platelet  count,  hemoglobin,  hematocrit, 
mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin 
concentration and red blood cell morphology  
Alkaline phosphatase, ALT , AST , Gamma -glutamyl -transferase (GGT), Bicarbonate, 
Calcium, Magnesium, Phos phorus, Chloride, Sodium, Potassium, Creatinine, Creatine 
kinase,  Direct  Bilirubin,  Indirect  Bilirubin,  Total  Bilirubin,  Total  Cholesterol,  LDL,  HDL,  Total 
Protein, Triglycerides,  
Glucose, amylase  
 
Coagulation  Prothrombin  time (PT) , Partial  thromboplastin  time (PTT)  
Thyroid  T3 (free),  T4 (free),  TSH 
Hepatitis 
markers  
 
 
Additional 
tests  HBV-DNA,  HbsAg, HbsAb,  HbcAb, HCV  RNA -PCR  (baseline)  
Serology:  anti-hepatitis A virus IgM, hepatitis B surface antigen and anti -hepatitis B core 
antigen  IgM, anti-hepatitis  C virus  IgG or IgM, anti-hepatitis  E virus  IgM (positive  IgM and/or 
IgM: do HEV -RNA PCR; if negative, patient can be included),  
Anti-VZV IgG, 
CYP2C9  haplotype  testing 
 

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  65  
Protocol  No. CBAF312AUS02   
 
 
Test Category  Test Name  
CD19+  Titers  
Pregnancy 
Test Serum  / Urine  pregnancy  test 
 
 
 
 
Clinical Chemistry  
Blood samples will be collected at the scheduled visits indicated in Table 8-1, and the 
parameters assessed will include: electrolytes (Na, K, Cl, bicarbonate, Ca, Mg, P), random 
glucose, albumin, alkaline phosphatase, creatinine, ALT, AST, GGT, amylase, total bilirubin, 
conjugated bilirubin, total cholesterol, CRP, triglyce rides, HDL and LDL.  
 
Hematology  
Blood samples will be collected at the scheduled visits indicated in Table 8 -1, and the 
parameters assessed will include: red blood cell count, total and differential WBC count 
(basophils, eosinophils, lymphocytes, monocytes, neutrophils), platelet count, hemoglobin, 
hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular 
hemoglobin concentration and red blood cell morphology.  
These  will be measured  at each visit by the central  laboratory  and will be communicated  to the 
site in case of a notable abnormality which could result to a dose change.  
 
Serology  
Serology  testing  will be conducted  at screening  only in order  to determine  the patient’s  immune 
status and eligibility for inclusion in the study with respect to a number of viruses;  
A positive  result  for HIV antibodies  or for any of the following  serological  markers  for hepatitis 
A, B, C, and E indicating acute or chronic infection is an exclusion criterion:  
• anti-hepatitis  A virus  IgM 
• hepatitis  B surface  antigen  and anti-hepatitis  B core antigen  IgM 
• anti-hepatitis  C virus  IgG or IgM 
• anti-hepatitis  E virus  IgM (positive  IgG and/or  IgM:  do HEV -RNA  PCR:  if negative, 
patient can be included).  
NOTE: If the treating physician suspects false positive Hepatitis serology results, such as an 
antibody pattern indicating acute Hepatitis infection but no corresponding eleva ted liver 
enzymes  and no signs  or symptoms  HEV -RNA  PCR  will be performed  and will be the deciding 
factor to determine whether the patient has hepatitis A, B, C, or E.  If negative, the treating 
physician may  document (in source  data and in a eCRF  comment)  that the serology  results are 
considered false positive and consider including the patient in the study.  
Anti-VZV IgG will be measured. Patients who are negative for varicella -zoster virus IgG 
antibodies at screening but may be re -screened after successful  vaccination.  
 

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  66  
Protocol  No. CBAF312AUS02   
CYP2C9 Testing  
CYP2C9  haplotype  testing  will be conducted  once  at the screening  visit to determine  the 
patient’s eligibility to enter into the study.  
 
 
 
 
 
 
8.4.2  Electrocardiogram  (ECG)  
Twelve -lead ECGs  will be performed  for all patients  at Screening,  Baseline  (Day  1; Pre-dose). 
Clinically  significant abnormalities should be recorded on the Medical History/Adverse event 
eCRF page.  
 
If the Day 1 (pre-dose)  12- lead ECG  assessment  meets  any of the following  criteria,  then dosing 
cannot be initiated.  
The criterion  are: 
1. Heart  rate < 55 bpm 
2. Cardiac  conduction  disorders  such as incomplete  left bundle  branch  block  or second 
degree AV block Mobitz type I (Mobitz I) (either history or observed at screening)  
3. Minor  ECG  findings:  PR interval  >200  msec;  QRS  duration  ≥120 msec;  QTcF  >430  msec 
(males); QTcF >450 msec (females)  
4. Any other  condition  which,  in the opinion  of the investigator,  has a potential  for AV 
conduction suppression  
5. Patients  diagnosed  with right  bundle  branch  block  
 
If none  are met, then the patient  can continue  with treatment.  
 
Additionally,  on baseline  Visit  1 (Day  1), heart  rate will be monitored  and measured  for 6 hours 
on a holter  telemetry  device  post initial  dose of siponimod.  If post-dose HR remains  < 45 bpm 
at the end of 6 -hour post -dose monitoring period, additional monitoring may be required (see 
Appendix 7).  
 
8.4.3  Optical Coherence Tomography  (OCT)  
OCT  is routinely  utilized  to assess  changes  or damages  to the retina  in a variety  of diseases  such 
as glaucoma, age -related macular degeneration or macular edema.  To monitor changes in the 
patients  retinal  thickness,  OCT  assessment,  measurement  if retinal  thickness,  will be performed 
on Visit  1 (Day  1: prior  to treatment;  can be done  5 days prior  to treatment  or on Day 1 prior  to 
treatment) and on Visit 4 (Day  84). The OCT  machine  used should  preferably  not be changed  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  67  
Protocol  No. CBAF312AUS02   
during the duration of the study.  The OCT can be performed by referring ophthalmologist or 
neurologists with clinical training and expertise to assess structural measurement o f retinal 
nerve fiber layer thickness, optic nerve head, and macular anatomy AND currently possess 
appropriate OCT equipment in -office.  
Please see Appendix 8  (Guidelines for Ophthalmic Examination and Management of Macular 
Edema) for further details and instructions.  
 
8.4.4  Pregnancy  and assessments of infertility  
Serum pregnancy test s will be conducted for all women who are of child bearing potential at 
the screening, baseline, EOT/S visits of the treatment period.  
Urinary  pregnancy tests will be conducted for all women of childbearing potential at all other 
scheduled clinic visits as  indicated in the schedule of assessments.  
Relevant participants can perform the urine pregnancy  test at home and report the result to the 
site. It  is important  that participants  are instructed  to perform  the urine  pregnancy  test first and 
only if the test  result is negative proceed with the administration of the study treatment. A 
communication process should be established with the participant so that the Site is informed 
of the pregnancy test results.  
 
Assessments  of Fertility  
Medical documentation of oophorectomy, hysterectomy, or tubal ligation must be retained as 
source  documents.  Subsequent  hormone  level  assessment  to confirm  the woman  is not of child 
bearing potential must also be available as source documentation in the fo llowing cases:  
1. surgical bilateral oophorectomy  without a hysterectomy  
2. reported  12 months  of natural  (spontaneous)  amenorrhea  with an appropriate  clinical 
profile.  
In the absence of the above medical documentation, FSH testing is required of any female 
patient, regardless of reported reproductive/menopausal status at screening/baseline.  
 
 
8.4.5  Other  safety  evaluations 
 
 
 
 
 
 
 
 
 
 
 

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  68  
Protocol  No. CBAF312AUS02   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Treatment Satisfaction  
The Treatment Satisfaction Question naire for Medication (TSQM -9) will be used to 
psychometrically evaluate the patients’ satisfaction with siponimod. The TSQM -9 is a sound 
and valid  measure  of the major  dimensions  of patients’  satisfaction  with medication  and a good 
predictor  of adherence  across  different  types  of medication  and patient  population  (Atkinson  et 
al 2004. ) 
 
Other assessments  
MS is associated  with a variable  combination  of symptoms,  including  sensory  loss, imbalance, 
mobility  loss, bladder  and bowel  dysfunction,  cognitive  dysfunction,  spasticity,  pain,  and sexual 
dysfunction. Measurement of these wide -ranging effects of MS on the lives of patients is 
beyond the scope of clinician -reported endpoints commonly used to evaluate therapeutic 
effectiveness in MS studies. Patient -reported outcome (PRO) measures prov ide an empirical 
assessment from the patient’s perspective of the benefits of treatment that cannot be gained 
from Magnetic Resonance Imaging (MRI), Expanded Disability Status Score (EDSS), or 
relapse measurement. The use of the C -SSRS (or equivalent) to d etect suicidal ideation or 
behavior is currently mandated in studies of CNS active drugs.  
 
Appropriateness  of safety  measurements  
The safety  assessments  in this study  are standard  for S1P modulator  treatment  in this indication 
and patient population.  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  69  
Protocol  No. CBAF312AUS02   
8.5 Additional  assessments  
8.5.1  Clinical  Outcome  Assessments  (COAs) 
Patient reported outcomes (PRO)  
The following  PROs  will be assessed  in this study.  These  questionnaires  will be administered  
to patients  per scheduled  visits  listed  in the schedule  of assessments.  
• Treatment  Satisfaction  Questionnaire  for Medical  (TSQM -9) 
  
  
While all screening assessments are expected to be conducted on -site, the option for home 
health nursing may be utilized to replace on -site study visits for the remainder of the trial.  In 
this case, home health nurses will provide technology to complete CO As. 
Trial Feedback  
At Visit 1 (baseline), Visit 4 (Day 84), and Visit 5 (Day 168/EOT/S), patients might be asked 
to complete  an optional  anonymized  questionnaire,  “Trial  Feedback  Questionnaire”  to provide 
feedback on their clinical trial experience.  Respon ses would be used to understand where 
improvements can be made in the clinical trial process.  This questionnaire is not meant to 
collect  data about  the patient’s  disease,  symptoms  or adverse  events  and therefore  would  not be 
considered to be trial data.  Should any spontaneous information be collected about AEs, it 
would be transferred to the safety database.  Patients may opt in or opt out of completing this 
questionnaire.  The data will be used to help understand  and conduct  clinical  trials  better  in the 
future.  
As per Section  4.6, during a Public Health emergency as declared by Local or Regional 
authorities i.e. pandemic, epidemic or natural disaster, that li mits or prevents on -site study 
visits, COA data may be collected remotely.  
 
  
 
 
 
 
  
 
 
 
 
 
  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  70  
Protocol  No. CBAF312AUS02   
 
 
 
8.5.3  Other  Assessments  
No additional  assessments/tests  will be performed  on patients  entered  into this study.  
 
 
9 Study  discontinuation  and completion  
9.1 Discontinuation  
9.1.1  Discontinuation  of study  treatment  
Study  treatment  can be interrupted  or discontinued  based  on investigator’s  judgement  and 
overall clinical assessment, including in the following cases:  
• Adverse  event  or serious  adverse  event  (e.g.,  Serious  infections,  Symptomatic 
bradyarrhythmia)  
• Abnormal  laboratory  value(s)  including  liver function  tests 
• Use of prohibited medications.  
All dose changes  must  be recorded  on the Dosage  Administration  Record  eCRF.  
Patients may voluntarily withdraw from the study for any reason at any time. They may be 
considered withdrawn if they  state an intention to withdraw, fail to return for visits or become 
lost to follow up for any other reason. If premature withdrawal occurs for any reason, the 
investigator must make every effort to determine the primary reason for a patient’s premature 
withdrawal from the study and record this information on the corresponding patient’s 
disposition eCRF page.  
Study  treatment  should  be discontinued  under the  following circumst ances:  
• Withdrawal  of informed consent  
• Pregnancy  
• Protocol  violation  that results  in a significant  risk to the patient’s  safety  
• Non-compliance  with study  treatment  
• Lost to follow  up 
• Emergence  of certain  adverse  events,  such as malignancy  (except  successfully  treated 
basal cell carcinoma), liver failure or, serious chronic infections (such as HIV).  
Note 1:  For a patient with a positive urine pregnancy test, study medication must be 
immediately  discontinued and a serum pregnancy test conducted. If the serum test is negative, 
the patient may restart study medication; if siponimod treatment has been interrupted  for 4 or 
more  consecutive  daily  doses,  treatment  must  be re-initiated  with the 5-day titration  pack.  If the 
serum test is positive, the patient can either be discontinued from the study or remain in the 
study  continuing  all scheduled  visits,  as above.  Restart of study  medication  after the pregnancy 
(and lactation)  will be considered  on a case by- case basis,  as above.  Women  who need  another 
disease modifying treatment during pregnancy will be withdrawn from the study.  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  71  
Protocol  No. CBAF312AUS02   
The investigator must also contact the IRT to register any patient discontinuations from study 
treatment . 
 
 
9.1.2  Withdrawal of informed consent  
Patients  may voluntarily  withdraw  consent  to participate  in the study  for any reason  at any time.  
Withdrawal of consent (WoC) occurs only when a patient does not want to participate in the 
study anymore; does not want any further visits or assessments and does not want any further 
study related contact.  
At the time a patient withdraws consent, the inve stigator should make every effort (e.g. 
telephone, e -mail, letter) to determine the primary reason for this decision and record this 
information on the Study Completion eCRF.  Study drug must be discontinued and no further 
assessments conducted.  All biologi cal material that has not been analyzed at the time of 
withdrawal must not be used.  Further attempts to contact the patient are not allowed unless 
safety findings require communicating or follow -up. 
Novartis will continue to retain and use all research res ults (data) that have already been 
collected for the study evaluation.  
 
 
9.1.3  Lost  to follow -up 
Study  treatment  should  be discontinued  if patient  is lost to follow -up. For patients  whose  status 
is unclear  because  they fail to appear  for study  visits  without  stating  an intention  to discontinue 
or withdraw, the investigator must show “due diligence” by documenting in the source 
documents  steps  taken  to contact  the patient,  e.g. dates  of telephone  calls,  registered  letters,  etc. 
A patient  will not be formally  considered  lost to follow -up until all efforts  to contact  the patient 
have been exhausted.  
 
 
9.1.4  Early  study  termination  by sponsor  
The study  can be terminated at any  time for any reason by  Novartis. This may  include reasons 
related to the benefit/risk assessment of participating in the study or for regulatory or medical 
reasons.  Should  this be necessary,  the patient  should  be seen as soon  as possible  and treated  for 
a prematurely  withdrawn  patient.  The investi gator  may be informed  of additional  procedures  to 
be followed in order to ensure that adequate consideration is given to the protection of the 
patient’s interests. The investigator will be responsible for informing IRBs of the early 
termination of the tria l. 
 
 
9.2 Study  completion  and post  study  treatment  
A patient will be considered a core treatment period completer when he/she has completed all 
treatment  period  visits,  up to the EOT/S  visit for the core treatment  period  and including  follow - 
up visits where required.  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  72  
Protocol  No. CBAF312AUS02   
 
 
The study will be considered completed when all individual patients have either completed or 
prematurely discontinued from the treatment period of the study. The maximum duration of a 
patient who completes the treatment Parts of the study coul d reach approx. 5 years.  
The investigator must provide follow -up medical care for all patients who prematurely 
withdrawn from the study, or must refer them for appropriate ongoing care.  
 
 
10 Safety  monitoring  and reporting  
10.1 Definition  of adverse  events  and reporting  requirements  
10.1.1  Adverse  events  
Adverse events must be recorded in the Adverse Events eCRF under the signs, symptoms or 
diagnosis associated with them, accompanied by the following information:  
• mild: usually  transient in nature and generally  not interfering with normal activities  
• mode rate: sufficiently  discomforting  to interfere  with normal activities  
• severe:  prevents  normal  activities  
All adverse events must be treated appropriately. Treatment may include one or more of the  
following:  
• no action taken (e.g. further observation only) 
• (investigational)  treatment  dosage  increased/reduced  
• (investigational)  treatment  interrupted/withdrawn  
• concomitant  medication or  non-drug therapy  given  
• non-drug therapy  given  
• patient  hospitalized/patient’s  hospitalization  prolonged  (see Section  10.1.2  for definition 
of SAE)  
• its outcome  (not recovered/not  resolved;  recovered/resolved;  recovered/resolved  with 
sequelae; fatal; or unknown)  
Once  an adverse  event  is detected,  it must  be followed  until its resolution  or until it is judged  to 
be permanent, and assessment must be made at each visit (or more frequently, if necessary) of 
any changes  in severity,  the suspected  relationship  to the study  drug,  the interventions  required 
to treat it, and the outcome.  
Information about common side effects already known about the investigational drug can be 
found in the Investigator Brochure (IB). This information will be  included in the patient 
informed  consent  and should  be discussed  with the patient  during  the study  as needed.  Any new 
information rega rding the safety profile of the medicinal product that is identified between IB 
updates will be communicated as appropriate, for example, via an Investigator Notification or 
an Aggregate  Safety  Finding.  New  information  might  require  an update  to the inform ed consent 
and has then to be discussed with the patient.  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  73  
Protocol  No. CBAF312AUS02   
The investigator must also instruct each patient to report any new adverse event (beyond the 
protocol observation  period)  that the patient,  or the patient’s  personal  physician,  believes  might 
reasonably  be related  to study  treatment.  This information  must  be recorded  in the investigator’s 
source  documents; however, if the AE meets the criteria of an SAE, it must be reported to 
Novartis.  
 
 
10.1.2  Serious  adverse  events  
An SAE is defined as any adverse event (appearance of (or worsening of any pre -existing)) 
undesirable  sign(s),  symptom(s)  or medic al conditions(s))  which  meets  any one of the following 
criteria:  
• fatal 
• life-threatening  
Life-threatening in the context of a SAE refers to a reaction in which the patient was at risk of 
death at the time of the reaction; it does not refer to a reaction that hypothetically might have 
caused death if it were more severe (please refer to the ICH -E2D Guidelines).  
• results  in persistent  or significant  disability/incapacity  
• constitutes  a congenital  anomaly/birth  defect  
• requires  inpatient  hospitalization  or prolongation  of existing  hospitalization,  unless 
hospitalization is for:  
• routine  treatment  or monitoring  of the studied  indication,  not associated  with any 
study drug deterioration.  
• elective  or pre-planned  treatment  for a pre-existing  condition  that is unrelated  to the 
indication under study and has not worsened since signing the informed consent  
• social  reasons  and respite  care in the absence  of any deterioration  in the patient’s 
general condition  
• treatment  on an emergency  outpatient  basis  for an event  not fulfil ling any of the 
definitions of a SAE given above and not resulting in hospital admission  
• is medically  significant,  e.g. defined  as an event  that jeopardizes  the patient  or may require 
medical or surgical intervention to prevent one of the outcomes listed above  
All malignant neoplasms will be assessed as serious under “medically significant” if other 
seriousness criteria are not met  
Medical  and scientific  judgment  should  be exercised  in deciding  whether  other  situations  should 
be considered  serious  reactions,  such as important  medical  events  that might  not be immediately 
life threatening or result in death or hospitalization but might jeopardize the patient or might 
require i ntervention to prevent one of the other outcomes listed above. Such events should be 
considered as “medically significant”. Examples of such events are intensive treatment in an 
emergency  room  or at home  for allergic  bronchospasm,  blood  dyscrasias  or convulsions  that do 
not result in hospitalization or development of dependency or abuse (please refer to the ICH - 
E2D Guidelines).  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  74  
Protocol  No. CBAF312AUS02   
Any suspected  transmission  via a medicinal  product  of an infectious  agent  is also considered  a 
serious adverse reaction.  
 
 
10.1.3  SAE reporting  
To ensure patient safety, every SAE, regardless of causality, occurring after the patien t has 
provided informed consent and until 30 days (after the last study visit/ following the last 
administration of study treatment if there are post -treatment follow -up visits with no required 
procedures) must be reported to Novartis safety within 24 hour s of learning of its occurrence. 
Detailed  instructions  regarding  the submission  process  and requirements  are to be found  in the 
investigator  folder  provided  to each site. Any SAEs experienced after the 30 day  period (after 
the last study visit/ following the last administration of study treatment if there are post - 
treatment follow -up visits with no required procedures) should only  be reported to Novartis if 
the investigator suspects a causal relationship to st udy treatment  
All follow -up information  for the SAE  including  information  on complications,  progression  of 
the initial SAE and recurrent episodes must be reported as follow -up to the original episode 
within  24 hours  of the investigator  receiving  the follow -up information.  An SAE  occurring  at a 
different time interval or otherwise considered completely unrelated to a previously reported 
one must be reported separately as a new event.  
If the SAE  is not previously  documented  in the Investigator’s  Brochure  or Package  Insert  (new 
occurrence) and is thought to be related to the study treatment, a CMO & PS Department 
associate may urgently require further information from the investigator for health authority 
reporting. Novartis may need to issue an In vestigator Notification (IN) to inform all 
investigators involved in any study with the same study treatment that this SAE has been 
reported.  
Suspected  Unexpected  Serious  Adverse  Reactions  (SUSARs)  will be collected  and reported  to 
the competent authoritie s and relevant ethics committees in accordance with EU Guidance 
2011/C 172/01 or as per national regulatory requirements in participating countries.  
The time of 30 days in the standard  text above  is the recommended  minimum  and the SAE  form 
should be submitted to Novartis Safety. A longer duration may be appropriate for drugs with 
particularly  long elimination  half-lives  or from  drug classes  with known  late occurring  effects, 
or when risk assessment/management objectives require prolonged safety monitoring. Please 
ensure the Informed Consent reflects this 30 day/Post Study Safety Contact.  
 
10.1.4  Pregnancy  reporting  
To ensure  patient safety, each  pregnancy  occurring  after signing  the informed  consent  must  be 
reported to Novartis within 24 hours of learning of its occurrence. The pregnancy should be 
followed up to determine outcome, including spontaneous or voluntary  termination, details of 
the birth,  and the presence  or absence  of any birth  defects,  congenital  abnormalities,  or maternal 
and/or newborn complications.  
Pregnancy should be recorded and reported by the investigator to the Novartis Chief Medical 
Office  and Patient  Safety  (CMO&PS).  Pregnancy  follow -up should  be recorded  on the same  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  75  
Protocol  No. CBAF312AUS02   
form  and should  include  an assessment  of the possible  relationship to  the investigational/study 
treatment.  
Any SAE experienced during pregnancy  and unre lated to the pregnancy  must be reported on a 
SAE form.  
 
 
10.1.5  Reporting  of study  treatment  errors  including  misuse/abuse  
Medication errors are unintentional errors in the prescribing, dispensing, administration or 
monitoring of a medicine while under the control of a healthcare professional, patient or 
consumer (EMA definition).  
Misuse  refers  to situations  where  the medicinal  product  is intentionally  and inappropriately  used 
not in accordance with the protocol.  
Abuse  corresponds  to the persistent  or sporadic,  intentional  excessive  use of a medicinal  product, 
which is accompanied by harmful physical or psychological ef fects.  
Study  treatment errors and uses outside of what is foreseen in the protocol will be recorded on 
the appropriate eCRF irrespective of whether or not associated with an AE/SAE and reported 
to Safety  only if associated  with an SAE.  Misuse  or abuse  will be collected  and reported  in the 
safety database irrespective of it being associated with an AE/SAE within 24 hours of 
Investigator’s awareness.  
 
Table 10 -1 Guidance  for capturing  the study  treatment  errors  including 
misuse/abuse  
Treatment  error  type Document  in Dosing  
CRF (Yes/No)  Document  in AE 
eCRF   
Complete  SAE form  
Unintentional  study 
treatment error  Yes Only if associated 
with an AE  Only if associated  with an 
SAE 
 
Misuse/Abuse  Yes Yes Yes, even  if not associated 
with a SAE  
For more information on AE and SAE definition and reporting requirements, please see the, 
respective sections.  
 
10.2 Additional  Safety  Monitoring  
10.2.1  Liver  safety  monitoring  
To ensure patient safety and enhance reliability in determining the hepatotoxic potential of an 
invest igational drug, a standardized process for identification, monitoring and evaluation of 
liver events has to be followed.  
Liver  events  are divided  into two categories:  
• Liver  events  of special  interest  (AESI)  which  consist  of elevations  of liver function  tests 
(LFTs)  
• Medically  significant  liver events  which  are considered  as serious  adverse  events  (SAEs) 
and which consist of marked elevations of LFTs and / or pre -specified adverse events.  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  76  
Protocol  No. CBAF312AUS02   
Please  refer  to Appendix  2 for complete  definitions  of liver events.  
Any liver event which meets the criteria for “medically significant” event as outlined should 
follow the standard procedures for S AE reporting. Every liver event as defined in Table 16 -1 
of Appendix  2 should  be followed  up by the investigator  or designated  personal  at the trial site 
as summarized below:  
• Repeating the LFT to confirm elevation as appropriate  
• Discontinuation  of the investigational  drug if appropriate  
• Hospitalization  of the patient  if appropriate  
• A causality  assessment  of the liver event  via exclusion  of alternative  causes  (e.g.,  disease, 
co-medications)  
• An investigation of  the liver  event which  needs  to be  followed until resolution.  
These investigations can include serology tests, imaging and pathology assessments, 
hepatologist’s consultancy, based on investigator’s discretion. All follow -up information, and 
the procedures performed should be recorded on appropriate eCRF pages, includ ing the liver 
event overview eCRF pages.  
NOTE: If  local  requirements  for liver safety  monitoring  are more  stringent  than those  outlined 
in this section of the protocol, then the local requirements will take precedence  
 
 
10.2.2  Prospective  suicidality  assessment  
The Columbia -Suicide Severity Rating Scale (C -SSRS) (Posner, 2011 ) is a questionnaire that 
prospectively assesses Suicidal Ideation and Suicidal Behavior.  The C -SSRS tool is 
administered via interview with the subject.  
The C-SSRS  must  be administered  at the visits  indicated  in Table  8-1. 
If the patient does not atten d the End of Treatment/Study Visit, the C -SSRS should be 
completed if the site has become aware of a potential suicide -related thought or behavior by 
other communications.  
If, at any time after screening the score is “yes” on item 4 or item 5 of the Suicid al Ideation 
section of the C -SSRS or “yes” on any item of the Suicidal Behavior section, except for the 
“Non -Suicidal Self -Injurious Behavior (NSSI) item, the patient must be referred to a mental 
health care professional for further assessment and/or treat ment. The decision on whether the 
study treatment should be discontinued is to be taken by the investigator in consultation with 
the mental health professional to whom the patient is referred.  
In addition,  all life-threatening  events  during  the study  must  be reported  as SAEs.  For example, 
if a patient  answers  “yes”  to one of the questions  in the Suicidal  Behavior  section,  an SAE  must 
be reported if the event was life -threatening.  
All events of “ Non-Suicidal Self -Injurious Behavior” (question in the Suicidal Behavior 
section) that meet the criteria for AEs (e.g. treatment emergent events or change in severity 
compared to baseline) should be reported as AEs. Patients reporting NSSI behaviors can be  
referred to a mental health care professional at the discretion of the investigator.  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  77  
Protocol  No. CBAF312AUS02   
 
 
10.2.3  Bradycardia  
This is considered  an AESI.  To ensure  patient  safety  and enhance  reliability  in determining  the 
bradycardia potential of an in vestigational drug, a standardized process for identification, 
monitoring  and evaluation  of bradycardia  events  has to be followed.  (Please  see Appendix  7 for 
instructions)  
Bradycardia  is defined as  any pre-dose HR  less 55  bpm or post -dose HR bpm less  than 45. 
 
11 Data  Collection  and Database  management  
11.1 Data  collection  
All data should be recorded, handled and stored in a way that allows its accurate reporti ng, 
interpretation and verification.  
Designated investigator staff will enter the data required by the protocol into the Electronic 
Case Report Forms (eCRF). The eCRFs have been built using fully validated secure web - 
enabled  software  that conforms  to 21 CFR  Part 11 requirements,  Investigator  site staff will not 
be given  access  to the EDC  system  until they have  been  trained.  Automatic  validation  programs 
check  for data discrepancies  in the eCRFs,  allow  modification  and/or  verification  of the entered 
data by the investigator staff.  
The investigator/designee  is responsible  for assuring  that the data (recorded  on eCRFs)  (entered 
into eCRF)  is complete,  accurate,  and that entry  and updates  are performed  in a timely  manner. 
The Investigator must ce rtify that the data entered are complete and accurate  
After  final database  lock,  the investigator  will receive  copies  of the patient  data for archiving  at 
the investigational site.  
All data should be recorded, handled and stored in a way that allows its accurate reporting, 
interpretation and verification.  
 
 
11.2 Database  management  and quality  control  
Novartis personnel (or designated CRO) will review the data entered by investigatio nal staff 
for completeness and accuracy. Electronic data queries stating the nature of the problem and 
requesting clarification will be created for discrepancies and missing values and sent to the 
investigational site via the EDC system. Designated investi gator site staff are required to 
respond promptly to queries and to make any necessary changes to the data.  
Concomitant  treatments  and prior  medications  entered  into the database  will be coded  using  the 
WHO  Drug  Reference  List, which  employs  the Anatomical  Therapeutic  Chemical  classification 
system.  Medical  history/current  medical  conditions  and adverse  events  will be coded  using  the 
Medical dictionary for regulatory activities (MedDRA) terminology.  
Randomization codes and data about all study treatment (s) dispensed to the patient and all 
dosage changes will be tracked using an Interactive Response Technology (IRT). The system  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  78  
Protocol  No. CBAF312AUS02   
will be supplied by a vendor, who will also manage the database. The data will be sent 
electronically to Novartis (or a designated CRO) at specific timelines.  
Once all the necessary actions have been completed and the database has been declared to be 
complete and accurate, it will be locked and made available for data analysis. Any changes to 
the database  after that time can only be made  after written  agreement  by Novartis  development 
management.  
 
 
11.3 Site monitoring  
Before study initiation, at a site initiation visit or at an investigator’s meeting, a Novartis / (or 
designated CRO) representative will review the protocol and data capture requirements (i.e. 
eSource DDE or eCRFs) with the investigators and their staff. During the study, Novartis 
employs  several  methods  of ensuring  protocol  and GCP  compliance  and the quality/integrity  of 
the sites’  data.  The field monitor  will visit the site to check  the completeness  of patient  records, 
the accuracy of data capture / data entry, the adherence to the protocol and to Good Clinical 
Practice, the progres s of enrollment, and to ensure that study treatment is being stored, 
dispensed,  and accounted  for according  to specifications.  Key study  personnel  must  be available 
to assist  the field monitor  during  these  visits.  Continuous  remote  monitoring  of each site’s  data 
may be performed by a centralized Novartis /delegated CRO/CRA organization. Additionally, 
a central analytics organization  may analyze data & identify  risks & trends for site  operational 
parameters, and provide reports to Novartis clinical teams  to assist with trial oversight.  
The investigator must maintain source documents for each patient in the study, consisting of 
case and visit notes (hospital or clinic medical records) containing demographic and medical 
information, laboratory data, electro cardiograms, and the results of any other tests or 
assessments. All information on eCRFs must be traceable to these source documents in the 
patient’s  file. The investigator  must  also keep  the original  informed  consent  form  signed  by the 
patient (a signed c opy is given to the patient).  
The investigator  must  give the monitor  access  to all relevant  source  documents  to confirm  their 
consistency  with the data capture and/or data entry. Novartis monitoring  standards  require  full 
verification  for the presence  of informed  consent,  adherence  to the inclusion/exclusion  criteria, 
documentation of SAEs, and of data that will be used for all primary varia bles. Additional 
checks of the consistency of the source data with the eCRFs are performed according to the 
study -specific monitoring plan. No information in source documents about the identity of the 
patients will be disclosed.  
 
 
11.4 Virtual  patient  coho rt 
This study  includes  a virtual  cohort,  i.e., the patient  will remain  in their own home  and complete 
study assessments via an online technology. The patient interacts with study personnel using 
online  communication  tools  which  incorporate  telemedicine.  This virtual  cohort  of the study  is 
being done in parallel to, but separate from, other sites that will conduct study visits in the 
traditional manner, i.e., with all assessments performed at the study center.  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  79  
Protocol  No. CBAF312AUS02   
The rationale for the virtual cohort is to make the trial accessible to patients who do not live 
close enough to a traditional pa rticipating trial site; and to unburden patients who may have 
ambulatory  challenges  and/or  who may have  family  and job responsibilities  that would  preclude 
their trial participation at a traditional trial site. Virtual assessments are less time -consuming, 
can be done independent of patient schedule, and do not require travel to a site.  
For patients  participating in the virtual cohort of the study, pre -screening is done remotely via 
a telephone call and informed consent is performed remotely using telemedici ne and an 
electronic consent form. Study drug is shipped directly to the patient’s home from a central 
certified and GCP compliant distribution center. Appropriate controls are used to ensure that 
the drug is received by the patient.  Lab samples and ECG re adings are collected from the 
patient, at the patient’s home, by certified healthcare personnel such as a mobile nurse 
practitioner or phlebotomist. Local lab sample collection centers are also incorporated to 
collected patient samples locally.  
Assessments  will only be conducted virtually if they can be done without affecting the 
wellbeing of the patient during the study and with the same level of scientific integrity as 
assessments conducted in a physical study center. Some assessments (e.g., EDSS, ) may 
require  the presence  of a trained  Registered  Nurse,  Nurse  Practitioner  or Physician  Assistant  in 
the patient’s  home.  If completed  in the patient’s  home,  EDSS  will be performed  by a Registered 
Nurse, Nurse Practitioner or Physician Assistant certified (Level C) to perform the test.  
While there are parts of study visits that require the virtual trial investigator to participate via 
telemedicine per protocol (for further detail please r eference the Study Virtual Cohort Site 
Operations Plan), the virtual investigator may participate in any visits or parts thereof via 
telemedicine.  
Data collected from patients participating in the virt ual cohort will be collected electronically 
using purpose -built technology and will be entered into RaveX manually by a virtual study 
coordinator.  The data is monitored remotely by CRAs. A central IRB is used for all 
investigators participating the virtual  study model, if used. AE/SAE (reporting, assessing and 
follow -ups) will be handled similarly to a traditional model, with the patient contacting study 
personnel or engaging local care for emergencies.  
The virtual  patient  cohort  may terminate  new study  enrollment  at the discretion  of the sponsor. 
In this case, any ongoing patients in this cohort will be followed per protocol through end of 
study.  Virtual study subject in prescreening will be offered alternative participation through 
our traditional cohort, when subject is amenable  
 
12 Data  analysis  and statistical  methods  
The analysis  will be conducted  on all patient  data at the end of the treatment  phase  of the study.  
Any data analysis  carried  out independently  by the investigator  should  be submitted  to Novartis 
before publication or presentation.  
 
12.1 Analysis  sets 
The Safety  Set includes  all patients  who received  at least one dose of study  treatment. 
All analyses will be performed using the Safety Set.  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  80  
Protocol  No. CBAF312AUS02   
 
 
12.2 Patient  demographics  and other  baseline  characteristics  
Demographic and other baseline data including disease characteristics will be l isted and 
summarized descriptively.  
Categorical  data will be presented  as frequencies  and percentages.  For continuous  data,  number 
of observations, mean, standard deviation, minimum, 25th percentile, median, 75th percentile, 
and maximum will be presented.  
Relevant medical histories and current medical conditions at baseline will be summarized by 
system organ class and preferred term.  
 
 
12.3 Treatments  
Categorical data will be summarized as frequencies and percentag es. For continuous data, 
number of observations, mean, standard deviation, minimum, 25th percentile, median, 75th 
percentile, and maximum will be presented.  
The duration of exposure in (days) to study medication will be summarized by means of 
descriptive s tatistics.  
Concomitant medications and significant non -drug therapies prior to and after the start of the 
study treatment will be listed and summarized according to the Anatomical Therapeutic 
Chemical (ATC) classification system.  
 
12.4 Analysis  of the prim ary endpoint(s)  
The primary aim of this study is to evaluate the overall safety and tolerability profile of 
siponimod  2 mg in patients  with relapsing  forms  of MS who are converting  from  existing  oral, 
injectable or infusion DMTs.  
 
 
12.4.1  Definition  of primary  endpoint(s)  
The primary endpoint is the occurrence of adverse event suspected to be related to study 
medication.  
 
 
12.4.2  Statistical  model, hypothesis,  and method  of analysis  
The number (and percentage) of patients with treatment eme rgent adverse events suspected to 
be related  to study  medication  will be summarized  by primary  system  organ  class  and preferred 
term.  The 95% confidence  interval for  the overall  rate of adverse  event  suspected  to be related 
to study medication will be calculated.  
A patient with multiple adverse events within a category  (overall, primary  system organ class, 
or preferred term) is only counted once towards the total of that category.  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  81  
Protocol  No. CBAF312AUS02   
The analysis  of the primary  variable  will also be  stratified  by pre-treatment.  
 
 
12.4.3  Handling  of missing  values/censoring/discontinuations  
No missing  data will be imputed.  All analyses  will be using  observed -case approach  
 
 
12.4.4  Sensitivity  and Supportive  analyses 
Sensitivity analyses  
No sensitivity  analyses are planned.  
 
Supportive analyses  
No supportive  analyses  are planned.  
 
 
12.5 Analysis  of secondary  endpoints  
12.5.1  Safety  endpoints  
Safety summaries (tables, figures) include only data from the on -treatment period with the 
exception  of baseline  data which  will also be summarized  where  appropriate  (e.g. change  from 
baseline summaries). In addition, a separate listing for death including  on treatment and post 
treatment deaths will be provided. In particular, summary  tables for adverse events (AEs) will 
summarize only on -treatment events, with a start date during the on -treatment period 
(treatment -emergent AEs).  
The on-treatment  period  lasts from  the date of first administration  of study  treatment  to 30 days 
after the date of the last actual administration of any study treatment.  
 
Adverse  events  
All information  obtained  on adverse  events will  be displayed  by patient.  
The number  (and percentage)  of patients  with treatment  emergent  adverse  events  (events  started 
after the first dose of study medication or events present prior to start of open -label treatment 
but increased in severity based on preferred term) will be summarized in the following ways:  
• By primary  system  organ class  and preferred  term 
• By primary  system organ  class, preferred term  and maximum  severity  
• By Standardized MedDRA  Query  (SMQ)  and preferred  term 
Separate summaries will be provided for adverse events and other significant adverse events 
leading to discontinuation.  
The number  (and proportion)  of patients  with adverse  events  of special  interest/related  to 
identified and potential risks will be summarized.  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  82  
Protocol  No. CBAF312AUS02   
A patient with multiple adverse events within a category  (overall, primary  system organ class, 
or preferred term) is only counted once towards the total of that category.  
In addition,  occurrence  of hospitalization  will be summarized  using  frequencies  and 
percentages.  
 
 
Vital signs 
All vital signs  data will be listed  by patient,  and visit/time  and if ranges  are available,  
abnormalities will be flagged. Summary statistics will be provided by visit/time.  
In addition,  change  in heart  rate from  Baseline  to 6-hour after first treatment  will be summarized.  
 
12-lead ECG  
All ECG  data will be listed  by patient  and visit,  abnormalities  will be flagged.  Summary 
statistics will be provided by visit.  
In addition,  change  in heart  rate (and other  vitals)  from  Baseline  to 6-hours  after first treatment, 
may be summarized. Please see protocol Section 8.4.2  
 
Clinical  laboratory  evaluations  
All laboratory data will be listed by patient and visit/time and if normal ranges are available 
abnormalities will be flagged. Summary statistics w ill be provided by visit/time. Shift tables 
using  the low/normal/high/  (low and high)  classification  will be used to compare  baseline  to the 
worst on -treatment value.  
 
12.5.2  Patient  report  outcomes  
Change in TSQM -9 from Baseline to each post -Baseline time point will be summarized by 
providing: number of observations, mean, standard deviation, minimum, 25th percentile, 
median, 75th percentile, and maximum.  
 
  
 
  
  
  
  
  
 
 
 
 
 

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  83  
Protocol  No. CBAF312AUS02   
 
 
 
 
 
 
 
  
 
  
 
  
 
  
 
 
 
 
 
 
 
 
12.7 Interim  analyses  
For the purpose  of earlier  dissemination,  an interim  analysis  on the safety  data will be conducted 
at the t ime of approximately 50 patients completing their Visit 5 (Day 168).  
Additional interim analyses may be conducted at additional time points based on study 
enrollment  to evaluate  continued  efficacy  and safety  data (for example,  50% enrollment).  These 
interim analyses will also allow for an evaluation of the infusion strata.  
 
 
 
Since  there  will be no hypothesis  testing  involved,  statistical  adjustment  for the interim  analysis 
will not be made at the stage of final analyses of efficacy and safety.  
 
12.8 Sample  size calculation  
12.8.1  Primary  endpoint(s)  
Sample size calculations were based on the rate of study drug related adverse events. During 
the first 6 months,  such an AE rate was observed  at 45% from  the pooled  data of patients  treated 
with fingolimod  0.5 mg/day  in studies  CFTY720D2301  and CFTY720D2302.  A sample  size of 
300 to 400 patients  will provide  us the precision  estimates  ranging  from  4.9%  to 5.6%  precision 
(half -width  of 95% confidence  interval)  of the estimated  rate of AE. Of the total sample  size, 

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  84  
Protocol  No. CBAF312AUS02   
approximately 80 -100 patients with prior infusion therapy exposure will be enrolled by 
balanced stratification.  
 
  
 
 
 
 
 
 
 
13 Ethical  considerations  and administrative  procedur es 
13.1 Regulatory  and ethical  compliance  
This clinical  study  was designed  and shall  be implemented,  executed  and reported  in accordance 
with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable 
local  regulations  (including  European  Directive  2001/20/EC,  US CFR  21), and with the ethical 
principles laid down in the Declaration of Helsinki.  
 
13.2 Responsibilities  of the investigator  and IRB/IEC  
Before  initiating  a trial, the investigator/institution  must  obtain  approval/favorable  opinion  from 
the Institutional  Review  Board/Independent  Ethics  Committee  (IRB/IEC)  for the trial protocol, 
written informed consent form, consent form updates, patient recruitment procedures (e.g., 
advertisements)  and any other  written  information  to be provided  to patients.  Prior  to study  start, 
the investigator is required to sign a protocol signatu re page confirming his/her agreement to 
conduct  the study  in accordance  with these  documents  and all of the instructions  and procedures 
found in this protocol and to give access to all relevant data and records to Novartis monitors, 
auditors,  Novartis  Quality  Assurance  representatives,  designated  agents  of Novartis,  IRBs/IECs, 
and regulatory authorities as required. If an inspec tion of the clinical site is requested by a 
regulatory authority, the investigator must inform Novartis immediately that this request has 
been made.  
 
13.3 Publication  of study  protocol  and results  
The protocol will be registered in a publicly accessible database such as clinicaltrials.gov and 
as required in EudraCT. In addition, after study completion ( e.g., defined as last patient last 
visit) and finalization  of the study  report  the results  of this trial will be submitted  for publication 
and posted  in a publicly  accessible  database  of clinical  trial results,  such as the Novartis  clinical 
trial results  website  and all required  Health  Authority  websites  (e.g. Clinicaltrials.gov,  EudraCT 
etc.) .  
For de tails on the Novartis publication policy including authorship criteria, please refer to the 
Novartis  publication  policy  training  materials  that were  provided  to you at the trial investigator 
meetings.  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  85  
Protocol  No. CBAF312AUS02   
13.4 Quality  Control  and Quality  Assurance  
Novartis maintains a robust Quality Management System (QMS) that includes all activities 
involved in quality  assurance and quality control, to ensure compliance with written Standard 
Operating Procedures as well as applicable global/local GCP regulations and ICH Guidelines.  
Audits of investigator sites, vendors, and Novartis systems are performed by auditors, 
independent  from  those  involved  in conducting,  monitoring  or performing  quality  control  of the 
clinical trial. The clinical audit process uses a knowledge/risk based appro ach. 
Audits  are conducted  to assess  GCP  compliance  with global  and local  regulatory  requirements, 
protocols and internal SOPs, and are performed according to written Novartis processes.  
 
14 Protocol  adherence  
This protocol  defines  the study  objectives,  the study  procedures  and the data to be collected  on 
study participants. Additional assessments required to ensure safety of patients should be 
administered as deemed necessary on a case by case basis. Under no circumstances including 
incidenta l collection is an investigator allowed to collect additional data or conduct any 
additional procedures for any purpose involving any investigational drugs under the protocol, 
other than the purpose of the study. If despite this interdiction prohibition, d ata, information, 
observation would be incidentally collected, the investigator shall immediately disclose it to 
Novartis and not use it for any purpose other than the study, except for the appropriate 
monitoring on study participants.  
Investigators ascert ain they will apply due diligence to avoid protocol deviations. If an 
investigator feels a protocol deviation would improve the conduct of the study this must be 
considered a protocol amendment, and unless such an amendment is agreed upon by Novartis 
and approved  by the IRB/IEC  and health  authorities,  where  required,  it cannot  be implemented.  
 
14.1 Protocol  Amendments  
Any change  or addition  to the protocol  can only be made  in a written  protocol  amendment  that 
must be approved by Novartis, health authorities where required, and the IRB/IEC prior to 
implementation.  
Only amendments that are required for patient safety may be implemented immediately 
provided the health authorities are subsequently notified by protocol amendment and the 
reviewing IRB/IEC is notified.  
Notwithstanding the need for approval of formal protocol amendments, the investigator is 
expected to take any immediate action required for the safety of any patient included in this 
study,  even  if this action  represents  a deviation  from  the protocol.  In such cases,  Novartis  should 
be notified of this action and the IRB/IEC at the study site should be informed according to 
local regulations.  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  86  
Protocol  No. CBAF312AUS02   
15 References  
Aslanis  V, Faller  T, Van de Kerkhof  E, Schubart  A, Wallström  E, Beyerbach  A. Siponimod 
(BAF312) (and/or its metabolites) penetrates into the CNS and distributes to white matter 
areas. Mult Scler J 2012; 18(10(suppl)): P792.  
Brown  B et al. Analysis  of cardiac  monitoring  and safety  data in patients  initiating 
fingolimod treatment in the home in clinic. BMC Neurol.  2019. 19(1): 287.  
Centers  for Disease  Control  and Prevention  (CDC).  Assessing  Immunity  to 
Varicella.  https://www.cdc.gov/chickenpox/hcp/immunity .html.  Accessed  May 22, 2018.  
Chiba  K et al. Role  of sphingosine  1-phosphate  receptor  type 1 in lymphocyte  egress  from 
secondary lymphoid tissues and thymus.  Cell Mol Immunol. 2006; 3(1): 11 -9. 
Chiba  K, Adachi  K. Sphingosine  1-phosphate  receptor  1 as a useful  target  for treatment  of 
multiple sclerosis. Pharmaceuticals (Basel). 2012; 5(5):514 –28. 
Chun  J and Hartung  HP. Mechanism  of action  of oral fingolimod  (FTY720)  in multiple 
sclerosis. Clin Neuropharmacol. 2010. 33(2); 91 -101. 
Coller JK, Krebsfaenger N, Klein K, Endrizzi K, Wolbold R, Lang T, et al. The influence of 
CYP2B6,  CYP2C9  and CYP2D6  genotypes  on the formation  of the potent  antioestrogen  Z-4- 
hydroxy -tamoxifen in human liver. Br J Clin Pharmacol. 2002; 54:157 –167. 
Fox E,  et al. Outcomes of switching directly to oral fingolimod from injectable therapies: 
Results of the  randomized,  open -label, multicenter, Evaluate Patient  Outcomes (EPOC) study 
in relapsing  multiple  sclerosis.  MS ARD.  DOI:  http://dx.doi.org/10.1016/j.msard.2014.06.005  
Gentile A, Musella A, Bullita S, et al.  Siponimod (BAF312) pre vents synaptic 
neurodegeneration  in experiential  multiple  sclerosis.  J neuoroinflammation  2016;  13(1);  207. 
Gergely  P et al. The selective  sphingosine  1-phosphate  receptor  modulator  BAF312  redirects 
lymphocyte distribution and has species -specific effects on heart rate. Br J Pharmacol 2012; 
167(5): 1035 -47. 
Gergely, P., et al., 2012. The selective sphingosine 1 -phosphate receptor modulator 
Siponimod  redirects  lymphocyte  distribution  and has species -specific  effects  on heart  rate. Br. 
J. Pharmacol.  167, 1035 –1047.  
Goodin et al, 2002. Disease modifying therapies in multiple sclerosis: report of the 
Therapeutics and Technology Assessment Subcommittee of the American Academy of 
Neurology  and the MS Council  for Practice  Guidelines.  Neurology.  2002  Jan 22; 58(2):169 - 
78. 
Jo E et al. S1P1 -selective  in vivo-active  agonists  from  high-throughput  screening:  off-the- 
shelf  chemical  probes  of receptor  interactions, signaling,  and fate. Chem Bio. 2005. 12(6): 
703-145. 
Kappos  et al. Siponimod  versus  placebo  in secondary  progressive  multiple  sclerosis:  a 
double -blind randomised, phase 3 study.  Lancet, 2018.  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  87  
Protocol  No. CBAF312AUS02   
Kappos  et al. Switching  from  natalizumab  to fingolimod:  A randomized,  placebo -controlled 
study in RRMS. Neurology. 2015 85(1):29 –39. doi:10.1212/WNL.0000000000001706  
Leurs CE, et al. 2018.  Switching natalizumab to fingolimod within 6 weeks reduces 
recurrence  of disease  activity  in MS patients.  Mult  Scler.  2018  Oct; 24(11):1453 -1460.  doi: 
0.1177/1352458517726381  
Lublin  et al. Defining  the clinical  course  of multiple  sclerosis:  the 2013  revisi ons. Neurology. 
2014 Jul 15; 83(3):278 -86. 
Matloubian  M et al. Lymphocyte  egress  from  thymus  and peripheral  lymphoid  organs  is 
dependent on S1P receptor 1.  Nature. 2004. 427(6972):355 -60. 
Mao-Draayer  et al. Siponimod  enriches  regulatory  T and B lymphocytes  in secondary 
progressive multiple sclerosis. JCI Insight. 2020. 13; 5(3):e134251.  
McDonald et al.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the 
International  Panel  on the diagnosis  of multiple  sclerosis.  Ann Neurol . 2001  July;  50(1):  121- 
7. 
Miners  JO, Birkett  DJ. Cytochrome  P4502C9:  an enzyme  of major  importance  in human  drug 
metabolism. Br J Clin Pharmacol. 1998; 45:525 –538. 
Montalban  et al 2010.  MRI  criteria  for MS in patients  with clinically  isolated  syndromes. 
Neurology. 2010 Feb 2; 74(5):427 -34. 
MS Society.  Secondary  Progressive  MS (SPMS).  https://www.mssociety.org.uk/what -is- 
ms/types -of-ms/secondary -progressive -spms. Accessed January 13, 2018.  
Mullershausen  F et al. Persistent  signaling  induced  by FTY720 -phosphate  is mediated  by 
internalized S1P1 receptors.  Nat Chem Biol. 2009. 5(6):428 -34. 
O’Sullivan  C, et al. The dual S1PR1/S1PR5  drug BAF312  (Siponimod)  attenuates 
demyelination in organotypic slice cultures.  J Neuroinflammation 2016; 12:31.  
Pilotto A, Seripa D, Franceschi M, Scarcelli C, Colaizzo D, Grandone E, et al. Genetic 
susceptibility  to nonsteroidal  anti-inflammatory  drug-related  gastroduodenal  bleeding:  role of 
cytochrome P450 2C9 polymorphisms. Gastroenterology. 2007; 133:465 –471. 
Polman  et al. 2005.  Diagnostic  criteria  for multiple  sclerosis:  2005  revisions  to the 
“McDonald Criteria.”  Ann Neurol. 2005 Dec; 58(6): 840 -6. 
Polman  et al. 2011.  Diagnostic  criteria  for multiple  sclerosis:  2010  Revisions  to the 
McDonald criteria. Ann Neurol. 2011 Feb; 69(2): 292 -302. 
Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, 
Melvin  GA, Greenhill  L, Shen  S, Mann  JJ. "The  Columbia –Suicide  Severity  Rating  Scale:  
Initial Validity and Internal C onsistency Findings From Three Multisite Studies With  
Adolescents and Adults" . American Journal of Psychiatry. 2011 Dec; 168 (12) : 1266 –77. 
Rovaris  et al. Secondary  progressive  multiple  sclerosis:  current  knowledge  and future 
challenges. Lancet Neurol. 200 6 Apr 5(4):343 -54. 

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  88  
Protocol  No. CBAF312AUS02   
Sanna,  M.G.,  et al., 2004.  Sphingosine  1-phosphate  (S1P)  receptor  subtypes  S1P1  and S1P3, 
respectively, regulate lymphocyte recirculation and heart rate. J. Biol. Chem. 279, 13839 – 
13848.  
Selmaj K, Li DK, Hartung HP, et al.  Siponimod for patients with relapsing –remitting 
multiple  sclerosis  (BOLD):  an adaptive  dose-ranging  randomized  phase  II. Lancet  Neurol 
2013; 12(8): 756 -67. 
Shah R et al. A First Look at the Characteristics of Patients w ith Multiple Sclerosis 
Initiating  Siponimod  Therapy  in the United  States.  Poster  presented  at: The 8th Joint 
ECTRIMS -ACTRIMS Meeting (MS Virtual); September 11 -13, 2020. P0835.  
Snelder N et al. Characterization and prediction of cardiovascular effects of f ingolimod and 
siponimod  using  a systems  pharmacology  modeling  approach.  J Pharmacol  Exp Ther.  2017. 
360(2):356 -367. 
Subei  AM and Cohen  JA. Sphingosine  1-phosphate  receptor  modulator  in multiple  sclerosis. 
CNS Drugs. 2015. 29(7):565 -75. 
Swanton  et al. 2006.  Modification of MRI  criteria for multiple sclerosis in patients with 
clinically  isolated  syndromes.  J Neurol  Neurosurg  Psychiatry.  2006  Jul; 77(7):  830-833. 
Swanton et al. 2007.  MRI  criteria for multiple sclerosis in patients presenting with clinically 
isolated  syndromes:  a multicenter  retrospective  study.  Lancet  Neurol  2007  Aug;  6(8):  677-86. 
Tintore et al.  Isolated demyelinating syndromes:  comparison of different MR imaging 
criteria  to predict  conversion  to clinical  definite  multiple  sclerosis.  AJNR  Am J Neruoradiol. 
2000 Apr 21(4): 702 -6. 
Tremlett  H, Yinshan  Z, Devonshire  V. National  history  of secondary -progressive  multiple 
sclerosis.  Mult Scler 2008; 14(3): 314 -24. 
Ufer et al. Impact  of siponimod  on vaccination  response  in a randomized,  placebo -controlled 
study. Neurol Neuroimmunol Neuroinflamm. 2017; 4:e398.  
Vormfelde S, Brockmoller J, Bauer S, Herchenhein P, Kuon J, Meineke I, et al. Relative 
impact  of genotype  and enzyme  induction  on the metabolic  capacity  of CYP2C9  in healthy 
volunteers. Clin Pharmacol Ther. 2009; 1:54 –61. 
Yuping  Chen,  Stephen  S. Ferguson,  Masahiko  Negishi,  and Joyce  A. Goldstein.  Induction  of 
Human  CYP2C9  by Rifampicin,  Hyperforin,  and Phenobarbital  Is Mediated  by the Pregnane 
X Receptor. Journal of Pharmacology  and Experimental Therapeutics February  1, 2004, 308  
(2) 495-501; DOI:  https://doi.org/10.1124/jpet.103.058818.  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  89  
Protocol  No. CBAF312AUS02   
16 Appendices  
16.1 Appendix  1: Vital  signs  
Notable  Vital  Signs  and Body  Weight  
Vital  Sign Variable  Notable  Criteria  
Pulse (beats/min)  >120  bpm 
Or 
< 55 bpm 
Systolic BP (mmHg)   160 mmHg 
Or 
 90 mm Hg 
Diastolic  BP (mmHg)   100mmHg  or 
 50 mmHg  
Temperature  (°C) >38.3  °C/ 101°F  
Body  weight  (kg) ± 7% from  baseline  weight  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  90  
Protocol  No. CBAF312AUS02   
16.2 Appendix  2: Liver  event  definition  and follow  up requirements  
Table  16-1 Liver  Event  and Laboratory  Trigger  Definitions  
Definition/  threshold  
LIVER  LABORATORY 
TRIGGERS  • 3 x ULN < ALT / AST ≤ 5 x ULN 
• 1.5 x ULN < TBL ≤ 2 x ULN 
 
LIVER  EVENTS  • ALT or AST > 5 × ULN 
• ALP > 2 × ULN (in the absence  of known  bone  pathology)  
• TBL > 2 × ULN (in the absence  of known  Gilbert  syndrome)  
• ALT or AST > 3 × ULN and INR > 1.5 
• Potential Hy’s Law cases (defined as ALT or AST > 3 × ULN and 
TBL > 2 × ULN (mainly  conjugated  fraction)  without  notable  increase 
in ALP to > 2 × ULN)  
• Any clinical  event  of jaundice  (or equivalent  term)  
• ALT or AST > 3 × ULN accompanied  by (general)  malaise,  fatigue, 
abdominal pain, nausea, or vomiting, or rash with eosinophilia  
• Any adverse  event  potentially  indicative  of a liver toxicity*  
 
*These  events  cover  the following:  hepatic  failure,  fibrosis  and cirrhosis,  and other  liver damage - 
related conditions; the non -infectious hepatitis; the benign, malignant and unspecified liver 
neoplasms TBL: total bilirubin; ULN: upper limit of normal  
 
 
Table  16-2 Follow  Up Requirements  for Liver  Events  and Laboratory  Triggers  
 
Criteria  Actions  required  Follow -up monitoring  
 
• Discontinue  the study  treatment 
immediately  
 
Potential  Hy’s Law casea 
 
 
 
ALT or AST 
 
 
 
> 8 × ULN 
 
 
 
 
 
 
> 3 × ULN and INR > 1.5 • Hospitalize,  if clinically 
appropriate  
• Establish  causality  
• Record  the AE and contributing 
factors (e.g., conmeds, med hx, 
lab) in the appropriate eCRF  
 
• Discontinue  the study  treatment 
immediately  
• Hospitalize  if clinically 
appropriate  
• Establish  causality  
• Record  the AE and contributing 
factors (e.g., conmeds, med hx, 
lab) in the appropriate eCRF  
• Discontinue  the study  treatment 
immediately  
• Hospitalize,  if clinically 
appropriate  
• Establish  causality  ALT,  AST,  TBL,  Alb, PT/INR,  ALP 
and GGT  until resolutionc 
(frequency  at investigator 
discretion)  
 
 
 
 
 
ALT,  AST,  TBL,  Alb, PT/INR,  ALP 
and GGT  until resolutionc 
(frequency  at investigator 
discretion)  
 
 
 
ALT,  AST,  TBL,  Alb, PT/INR,  ALP 
and GGT  until resolutionc 
(frequency  at investigator 
discretion)  
 

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  91  
Protocol  No. CBAF312AUS02   
 
 
Criteria  Actions  required  Follow -up monitoring  
• Record  the AE and contributing 
factors (e.g., conmeds, med hx, 
lab) in the appropriate eCRF  
 
• Repeat  LFT within  48 hours  
• If elevation  persists,  continue 
follow -up monitoring  
 
> 5 to ≤ 8 × ULN 
 
 
 
 
 
 
 
 
> 3 × ULN accompanied 
by symptomsb 
 
 
 
 
> 3 to ≤ 5 × ULN (patient 
is asymptomatic)  
 
ALP (isolated)  
 
 
> 2 × ULN (in the 
absence  of known  bone 
pathology)  
 
 
TBL (isolated)  
 
 
 
> 2 × ULN (in the 
absence  of known 
Gilbert  syndrome)  
 
 
 
 
> 1.5 to ≤ 2 × ULN 
(patient  is asymptomatic)  • If elevation  persists  for more  than 
2 weeks, discontinue the study 
drug 
• Establish  causality  
• Record  the AE and contributing 
factors (e.g., conmeds, med hx, 
lab) in the appropriate eCRF  
• Discontinue  the study  treatment 
immediately  
• Hospitalize  if clinically 
appropriate  
• Establish  causality  
• Record  the AE and contributing 
factors (e.g., conmeds, med hx, 
lab) in the appropriate eCRF  
• Repeat  LFT within  the next week  
• If elevation  is confirmed,  initiate 
close observation of the patient  
 
• Repeat  LFT within  48 hours  
• If elevation  persists,  establish 
causality  
• Record  the AE and contributing 
factors (e.g., conmeds, med hx, 
lab) in the appropriate eCRF  
 
• Repeat  LFT within  48 hours  
• If elevation  persists,  discontinue 
the study drug immediately  
• Hospitalize  if clinically 
appropriate  
• Establish  causality  
• Record  the AE and contributing 
factors (e.g., conmeds, med hx, 
lab) in the appropriate eCRF  
• Repeat  LFT within  the next week  
• If elevation  is confirmed,  initiate 
close observation of the patient  ALT,  AST,  TBL,  Alb, PT/INR,  ALP 
and GGT  until resolutionc 
(frequency  at investigator 
discretion)  
 
 
 
 
 
ALT,  AST,  TBL,  Alb, PT/INR,  ALP 
and GGT  until resolutionc 
(frequency  at investigator 
discretion)  
 
 
 
Investigator  discretion  
Monitor  LFT within  1 to 4 weeks  
 
 
 
Investigator  discretion  
Monitor  LFT within  1 to 4 weeks 
or at next visit  
 
 
 
 
ALT,  AST,  TBL,  Alb, PT/INR,  ALP 
and GGT  until resolutionc 
(frequency  at investigator 
discretion)  
Test for hemolysis (e.g., 
reticulocytes, haptoglobin, 
unconjugated  (indirect ) bilirubin)  
 
Investigator  discretion  
Monitor  LFT within  1 to 4 weeks 
or at next visit  
 

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  92  
Protocol  No. CBAF312AUS02   
 
 
Criteria  Actions  required  Follow -up monitoring  
• Discontinue  the study  treatment 
immediately  
 
Jaundice  
 
 
 
 
 
 
Any AE potentially 
indicative  of a liver 
toxicity*  • Hospitalize  the patient  
• Establish  causality  
• Record  the AE and contributing 
factors (e.g., conmeds, med hx, 
lab) in the appropriate eCRF  
• Consider study treatment 
interruption  or discontinuation  
• Hospitalization  if clinically 
appropriate  
• Establish  causality  
• Record  the AE and contributing 
factors (e.g., conmeds, med hx, 
lab) in the appropriate eCRF  ALT,  AST,  TBL,  Alb, PT/INR,  ALP 
and GGT  until resolutionc 
(frequency  at investigator 
discretion)  
 
 
 
 
 
Investigator  discretion  
 
aElevated  ALT/AST  > 3 × ULN and TBL > 2 × ULN but without  notable  increase  in ALP to > 2 × ULN 
b(General) malaise, fatigue, abdominal pain, nausea, or vomiting, or rash with eosinophilia 
cResolution  is defined  as an outcome  of one of the following:  (1) return  to baseline  values,  (2) stable 
values at three subsequent monitoring visits at least 2 weeks  apart, (3) remain at elevated level  
after a maximum of 6 months, (4) liver transplantation, and (5) death.  
Based on investigator’s discretion investigation(s) for contributing factors for the liver event can 
include:  serology  tests,  imaging  and pathology  assessments,  hepatologist’s  consultancy;  obtaining  more 
detailed history of symptoms and prior or concurrent diseases, history of concomitant drug use, 
exclusion of underlying liver disease.  
 
 
16.3 Appendix  3: Specific  Renal  Alert  Criteria  and Actions  and Event 
Follow -up 
Guidance  on monitoring  patients  with elevated  blood  pressure : Patients who have at least two 
out of the three sitting readings of blood pressure (systolic BP  ≥ 140 and/or diastolic BP ≥ 90 
mmHg) should be followed up in one month by an unscheduled visit if the scheduled visit is 
not due. Should systolic BP ≥ 140 and/or diastolic BP  ≥ 90 mmHg values  will be confirmed 
in two sitting readings out of three in the second visit, the patient sh ould be referred to his 
primary care physician, an independent internist or to the specialty hypertension clinic for 
evaluation, diagnosis and treatment of hypertension. A standard referral letter provided by 
Novartis  should  explain a reason  for referral  and the information  about the  investigational 
drug (BAF312).  
Patients with BP values of >180/110 mmHg on any visit during the study should be 
immediately referred to evaluation, diagnosis and treatment of hypertension.  
The study  drug should  not be discontinued,  unless  the physician  has a reason  to do so. 
A newly  diagnosed  hypertension  as well as an aggravation  of a preexisting  condition  must 
be reported as an AE.  
Guidance on monitoring of patients with notable lymphopenia : The absolute total WBC, 
neutrophil and lymphocyte counts will be measured at each visit by the  central  laboratory.  If 

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  93  
Protocol  No. CBAF312AUS02   
the circulating lymphocyte level drops to <0.2 x109/L when the patient is receiving the 
minimum study drug dose allowed in the study protocol,  the lymphocyte count should be 
repeated in one week by  the central lab to confirm the reading. If  the repeat test confirms the 
lymphocyte count is below 0.2x109/L or 200 cells/mm3, the study  drug must be interrupted 
and the lymphocytes count needs to be m onitored weekly  until the level  returns  to 0.2 x 109/L, 
then monthly until the level reaches 0.6x109/L values. The patient  should be continuously 
evaluated and monitored for infections.  
Re-initiation of the study drug can only be considered once the lympho cyte counts increase 
above 0.6x109/L. 
Guidance on monitoring of patients with symptoms of neurological deterioration inconsistent  
with MS course : Should a patient develop any unexpected neurological or psychiatric 
symptom/signs in the  opinion of investigator (e.g. cognitive deficit, behavioral changes, 
cortical visual disturbances or any other neurological cortical symptoms/signs any 
symptom/sign suggestive of an increase of intracranial pressure) or accelerated neurological 
deterioration, the investigator should schedule a complete physical and neurological 
examination  as soon  as possible before beginning any treatment.  
Guidance on monitoring of p atients with infections : All infections that develop during the 
study will be reported as AEs on the respective AE  eCRF pages. Treatment and additional 
evaluations  will be performed  at discretion  of the investigator.  
The investigator should remind the pati ent of the risk of infections and instruct them to 
promptly report any symptoms of infections to the investigator. The patients must also be 
reminded to always carry their Patient Information Card (with site contact information and 
which identifies them as  participants in a clinical study with an investigational agent with 
potential immunosuppressive effects) and to show this to any local healthcare provider they 
may consult and ask that the Primary Treating Physician be contacted.  
In the case of suspected or confirmed serious or atypical infection, BAF312 treatment 
interruption should be considered. The investigator should inform the Novartis Medical 
Advisor of any such cases. The elimination half -life of approximately 30 hours allows 
washout of the compoun d within a week.  
When  evaluating a patient with a  suspected infection,  the most sensitive tests available should 
be used (i.e. that directly detect the pathogen, as with PCR).  
The investigator should consider early treatment with specific antimicrobial therapy on the 
basis of clinical diagnosis or suspicion thereof (e.g. anti viral treatment for herpes simplex or 
zoster) in consultation with infectious disease experts, as appropriate. The investigator should 
inform the Novartis Medical Advisor of any such cases.  
Investigators should consider the added immunosuppressive effects of corticosteroid therapy 
for treatment of MS attack/relapse and increase vigilance regarding infections during such 
therapy and in the weeks following administration.  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  94  
Protocol  No. CBAF312AUS02   
16.4 Appendix  4: List of generic  names  of potent  inhibitors/inducers 
of CYP2C9/CYP3A4  
The aim of this document is to provide a specific list of drugs that should not be co - 
administered with siponimod,  and a list of drugs that should only be used with a dditional 
vigilance.  
Due to the constant information arising on drugs, these lists are by no mean exhaustive and 
medical judgment should always prevail. These lists are adapted to the patient population and 
the exclusion criteria of the CBAF312AUS02.  
Sipon imod is extensively metabolized, mainly via CYP2C9 (79.3%), followed by CYP3A4 (18.5%). 
CYP2C9 is polymorphic and the genotype influences the fractional contributions of the two oxidative 
metabolism  pathways  to overall  elimination.  Physiologically  based  PK modeling  indicates  a differential 
CYP2C9  genotype -dependent  inhibition  and induction  of CYP3A4  pathways.  With  decreased  CYP2C9 
metabolic  activity  in the respective  genotypes,  a larger  effect  of the CYP3A4  perpetrators  on siponimod 
exposure is anticipated.  
Because  of a significant  increase  in exposure  to siponimod, concomitant  use of siponimod  and 
drugs  that cause  moderate  CYP2C9  and moderate  or strong  CYP3A4  inhibition  is not allowed. 
This concomitant  drug regimen  can consist of a moderate  CYP2C9/CYP3A4  dual inhibitor  (e.g., 
fluconazole) or a moderate CYP2C9 inhibitor in combination with a separate - moderate or 
strong CYP3A4 inhibitor.  Caution should be exercised for concomitant use of siponimod with 
moderate CYP2C9 inhibitors.  
Because  of a significant  decrease  in siponimod  exposure,  concomitant  use of siponimod  and drugs  that 
cause  moderate  CYP2C9  and strong  CYP3A4  induction  is not allowed  for all patients.  This concomitant 
drug regimen can consist of moderate CYP2C9/strong CYP3A4 dual inducer (e.g., rifampin or 
carbamazepine)  or a moderate  CYP2C9  inducer  in combination  with a separate  strong  CYP3A4  inducer. 
Caution should be exercised for concomitant use of MAYZE NT with moderate CYP2C9 inducers.  
 
Table  16-3 Dual  moderate  CYP2C9/strong  or moderate  CYP3A4  inhibitors  
 
Fluconazole   
 
 
Table  16-4 Moderate  CYP2C9  inhibitors  
 
Phenybutazone  Oxandrolone  Milk thistle  
Ataciguat  AZD1981  Azapropazone  
Tienilic  acid Piperine  Bucolome  
Fluconazole  amiodarone  Benzbromarone  
 
 
Table  16-5 Strong  CYP3A4  inhibitors  
 
Viekira  Pak Elvitegravir/ritonavir  Telithromycin  
Indinavir/ritonavir  Saquinavir/ritonavir  Grapefruit  juice  DS 

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  95  
Protocol  No. CBAF312AUS02   
 
Tipranavir /ritonavir  Lopinavir/ritonavir  Ceritinib  
Ritonavir  Itraconazole  Conivaptan  
Cobicistat  Voriconazole  Nefazodone  
Ketoconazole  Mifepristone  Nelfinavir  
Indinavir  Mibefradil  Saquinavir  
Troleandomycin  LCL161  Ribociclib  
Telaprevir  Clarithromycin  Idelalisib  
Danoprevir/ritonavir  Posaconazole  Boceprevir  
 
 
Table  16-6 Moderate  CYP3A4  inhibitors  
 
Erythromycin  GSK2647544  Grapefruit  juice  
Fluconazole  Aprepitant  Tofisopam  
Atazanavir/ritonavir  Casopitant  Cyclosporine  
Darunavir  Amprenavir  ACT -178882  
Diltiazem  Faldaprevir  Ciprofloxacin  
Darunavir/ritonavir  Imatinib  Magnolia  vine (Schisandra 
sphenanthera)  
Dronedarone  Verapamil  Isavuconazole  
Crizotinib  Ravuconazole  Cimetidine  
Atazanavit  Nutepitant  FK1706  
Letermovir  Nilotinib   
 
 
Table  16-7 Dual  moderate  CYP2C9/moderate  or strong  CYP3A4  inducers  
 
Rifampin  Enzalutamide  
 
 
Table  16-8 Moderate  CYP2C9  inducers  
 
Rifampin  Enzalutamide  
Ritonavir   

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  96  
Protocol  No. CBAF312AUS02   
Table  16-9 Strong  CYP3A4  inducers  
 
Rifampin  Carbamazepine  
Mitotane  Enzalutamide  
Avasimibe  St John’s  Wort  extract  
Rifapentine  Lumacaftor  
Apalutamide  Rifabutin  
Phenytoin  Phenobarbital  
 
 
Table  16-10 Moderate  CYP3A4  inducers  
 
Ritonavir  and St John’s  Wort  Nafcillin  
Semagacestat  Talviraline  
Efavirenz  Lopinavir  
Tipranavir  and ritonavir  Daclatasvir  and asunaprevir  and beclubuvir  
Dabrafenib  Modafinil  
Lesinurad  PF-06282999  
Bosentan  Etravirine  
Genistein  Lersivirine  
Thioridazine  Telotristat ethyl  
 
 
*Source:  University  of Washington,  Drug  Interaction  Database  (www.druginteractioninfo.org).  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  97  
Protocol  No. CBAF312AUS02   
16.5 Appendix  5: Asses sing Immunity  to Varicella  
(https://www.cdc.gov/chickenpox/hcp/immunity .html)  
 
Evidence  of immunity  to varicella  includes  any of the following: 
Documentation of age -appropriate varicella vaccination;  
• Preschool -age children  (i.e., age 12 months  through  3 years):  1 dose 
• School -age children,  adolescents,  adults:  2 doses  
• Laboratory  evidence of immunity  or laboratory  confirmation of disease  
• Birth  in the United  States  before  1980  (Should  not be considered  evidence  of immunity 
for health care personnel, pregnant women, and immunocompromised persons)  
• Diagnosis  or verification  of a history  of varicella  or herpes  zoster  by a health  care provider  
To verify  a history  of varicella, health  care providers  should  inquire about:  
• an epidemiologic  link to another  typical  varicella  case or to a laboratory  confir med case, 
or 
• evidence  of laboratory  confirmation, if testing was  performed at the time of acute disease  
Persons  who have  neither  an epidemiologic  link nor laboratory  confirmation  of varicella  should 
not be considered as having a valid history of disease. For these persons, a second dose of 
vaccine is recommended if they previously received only one dose. If a health care provider 
verifies the diagnosis based on the above criteria, then vaccinat ion is not needed  
 
 
16.6 Appendix  6: Teriflunomide  Accelerated  Elimination  Program  (for 
patients treated with teriflunomide at screening or within 8 
months prior to screening)  
All patients  treated  with teriflunomide  at screening  or within  8 months  prior  to screening  should 
undergo accelerated teriflunomide elimination program. This can b e done anytime during the 
Screening Period if a switch in therapy for the patient is imminent or during the Treatment 
Period, Visit 1, after all inclusion criterion are met by the patient.  
Recommended rapid elimination procedure is the administration of or al cholestyramine 8 g 
three times per day for 11 days.  If patients do not tolerate this regimen, then the dosage may 
be reduced to 4 g three times per day.  Teriflunomide levels are not required for this study 
however could be completed as part of standard of care.  
If tolerability issues persist, cholestyramine administration does not need to occur on 
consecutive days unless there is an acute need to lower teriflunomide levels.  
As an alternative to cholestyramine, oral activated charcoal administered as 50 g twice a day 
for 11 days may be used.  
It needs  to be documented  in the eCRF  which  elimination  treatment  was used.  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  98  
Protocol  No. CBAF312AUS02   
16.7 Appendix  7: Recommendat ions for the management  of 
bradycardia  
Initiating  treatment  results  in a decrease  in HR. If any of the following  abnormalities  are present 
after 6 hrs. (even in the absence of symptoms), additional monitoring should be conducted:  
• Day 1: HR 6 hrs.  post-dose <45 bpm 
If post-dose symptomatic  bradycardia,  bradyarrhythmia,  or conduction  related  symptoms  occur, 
or there  is evidence  of new-onset  second -degree  or higher  AV block  or QTc ≥500 msec,  initiate 
appropriate management; monitor ECG and symptoms until resolved if no pharmacological 
treatment is required.  
The study site personnel should be particularly mindful of patien ts who have a low pulse at 
baseline (spontaneously  or through drug -induced ß -receptor blockade), prior  to administration 
of the study drug. A cardiologist should be consulted if needed.  
Atropine (subcutaneous or intravenous) is recommended as the first -line treatment of 
bradycardia, up to a maximum daily dose of 3 mg.  
Furthermore, the common guidelines for treatment of bradycardia (e.g. ACLS guidelines) 
should be followed as appropriate:  
• In case of clinical  symptoms  of bradycardia,  administration  of atropine  1 mg, with 
repeated administration in 3 -5 minutes is recommended.  
• If heart  rate and/or  blood  pressure  remain  unresponsive,  consider  administration  of 
dopamine drip 5 -20 ug/kg/min or epinephrine drip 2 -10 ug/min.  
• Transcutaneous pacing may  also be considered.  
• In the setting  of decreased  blood  pressure,  isoproterenol  should  be avoided  or used with 
caution.  
• If a patient  requires  treatment  for brady cardia/bradyarrhythmia  during  the first dose,  the 
patient should be hospitalized for overnight monitoring and this monitoring procedure 
should be repeated for the second dose of study drug.  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  99  
Protocol  No. CBAF312AUS02   
16.8 Appendix  8: Guidelines  for Ophthalmic  examination  and 
management of Macular Edema  
A complete ophthalmic examination and Optical Coherence Tomography (OCT) assessment 
are scheduled  at baseline  (Day  1) and Visit  4 (Day  84), as indicated  in the assessment  schedules 
for both CP study assessments ( Table 8 -1). 
 
This appendix provides details of the ophthalmic examination requirements in the study.  
 
A standard visual acuity chart with equal space between letters and between lines should be 
used for the visual  acuity  assessment.  As noted  in Section  8.4.5 ., the OCT  machine  used should 
preferably not be changed during the course of the study to allow for comparison of central 
foveal thickness within each patient across time poin ts. 
(1) Ophthalmic  monitoring  for general  MS population  Baseline  visit: 
At the baseline visit this eye examination will include;  
• ophthalmic history  
• best corrected  visual  acuity  measurement  
• ophthalmoscopy  (may  include  contact  lens biomicroscopy  to examine  the macula  and 
optic disc).  
• measurement  of central  foveal  thickness  by OCT  (required  for all patients  regardless  of 
the results of visual acuity or ophthalmoscopy).  
N.B.  Ophthalmic  findings  should  be recorded.  
 
If there is a suspicion of macular edema by ophthalmoscopy and increased central foveal 
thickness by OCT, then a fluorescein angiogram may be performed (at the discretion of the 
ophthalmologist). Patients  with diagnosed macular edema at baseline  should  discontinue  from 
the study.  
 
Visit 4 
At scheduled  study  visits  the eye examination  will include;  
• ophthalmic history  
• best corrected visual acuity  measurement  
• ophthalmoscopy  (may  include  contact  lens biomicroscopy  to examine  the macula  and 
optic disc).  
• measurement  of central  foveal  thickness  by OCT  (required  for all patients  regardless  of 
the results of visual acuity or ophthalmoscopy).  

Novartis  
Amended  Protocol  Version  No. 05 (clean)  Confidential  Page  100  
Protocol  No. CBAF312AUS02   
N.B.  Ophthalmic  findings  should  be recorded.  
 
During  the study  if there  are complaints  of decreased  vision  or identification  of worsening  visual 
acuity  (equal  to or more  than two lines  on a standard  eye chart  using  best corrected  vision)  then 
an unscheduled ophthalmic exam should be performed at which the eye examination will 
include;  
• best corrected visual acuity  measurement  
• ophthalmoscopy  (may  include  contact  lens biomicroscopy  to examine  the macula  and 
optic disc).  
• measurement  of central  foveal  thickness  by OCT  
N.B.  Ophthalmic  findings  should  be recorded.  
 
The OCT  can be performed  by referring  ophthalmologists  or neurologists  with clinical  training 
and expertise  to assess  structural  measurement  of retinal  nerve  fiber  layer  thicknes s, optic  nerve 
head, and macular anatomy AND currently possess appropriate OCT equipment in -office.  
 
In case of suspected macular edema based on the  ophthalmoscopy or if a relevant increase of 
central foveal thickness is observed, then a fluorescein angiogram may be performed to 
diagnose  and characterize  macular  edema  (at the discretion  of the ophthalmologist),  if present.  
